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ABSTRACT 
 
 
Background. Primary and acquired resistance to selective Epidermal 
growth factor receptor (EGFR) inhibitors remains the most significant obstacle 
to the success of these targeted agents in cancer therapy. The mechanisms of 
resistance involve the activation of alternative signaling pathways able to 
bypass EGFR blockade, and Akt activation and VEGF induction have been 
described in EGFR inhibitor-resistant tumors. Combined inhibition of EGFR 
and other signaling proteins has become an effective approach to efficiently 
inhibit compensatory escape pathways, stimulating the search for further 
determinants of resistance as basis for novel therapeutic strategies.   
Aim of the study. The purpose of this study is to examine the signaling 
mechanisms operating in human cancers with intrinsic or acquired resistance to 
EGFR-targeted therapies and responsible for the lack of response to EGFR 
inhibitors. To this aim, we established human cancer cell lines with various 
degrees of EGFR expression and sensitivity to EGFR inhibitors and analyzed 
signal transducers under the control of EGFR-dependent and -independent 
pathways.  
Results. Multitargeted inhibitor vandetanib (ZD6474) inhibited human 
endothelial cells survival thanks to inhibition of both VEGFRs and EGFR 
signaling pathways. Vandetanib also inhibited the growth and the 
phosphorylation of Akt and its effector p70S6 kinase in both, wild-type and 
EGFR inhibitor-resistant human colon, prostate and breast cancer cells. We 
found that the resistant cell lines exhibit, as common features, VEGFR-1/Flt-1 
overexpression, increased secretion of VEGF and placental growth factor 
(PlGF), and augmented migration capabilities, and that vandetanib is able to 
antagonize them. Accordingly, a new kinase assay revealed that in addition to 
VEGFR-2, RET and EGFR, vandetanib efficiently inhibits also VEGFR-1; this 
capability plays a key role in determining its activity on EGFR drugs-resistant 
tumors. The contribution of VEGFR-1 to the resistant phenotype was further 
supported by the demonstration that VEGFR-1 silencing in resistant cells 
restored sensitivity to anti-EGFR drugs and impaired migration capabilities, 
while exogenous VEGFR-1 overexpression in wild-type cells conferred 
resistance to these agents.  
Conclusions. This study demonstrates that VEGFR-1 contributes to 
anti-EGFR drugs resistance in different human cancer models. Moreover, 
vandetanib inhibits VEGFR-1 activation, cell proliferation and migration, 
suggesting its potential utility in patients resistant to EGFR inhibitors. Since 
vandetanib is successfully under investigation in several clinical studies, these 
data may be important for its clinical development. 
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1. BACKGROUND  
 
 
1.1 The Epidermal growth factor receptor (EGFR) as a target for cancer 
therapy. 
 
In the last decade significant progress has been made in the 
understanding of the molecular mechanisms which are responsible for human 
cancer development and progression. The uncontrolled production of specific 
growth factors and the abnormal, enhanced expression on the cell membranes 
of growth factor receptors to which growth factors selectively bind play a key 
role in autonomous and deregulated proliferation of cancer cells, induction of 
angiogenesis, and metastasis. The majority of human epithelial cancers are 
marked by functional activation of growth factors and receptors of the 
erbB/HER family, which are involved in their formation and maintenance. This 
family consists of four distinct, but structurally similar, trans-membrane 
tyrosine kinase (TK) receptors, named erbB-1/HER1 (better known as 
Epidermal growth factor receptor, EGFR), erbB-2/HER2, erbB-3/HER3 and 
erbB-4/HER4 (Hynes and Lane 2005; Citri and Yarden 2006; Ciardiello and 
Tortora, 2008). 
The EGFR gene encodes a 170kDa trans-membrane glycoprotein 
containing 1186 amino acids. The receptor consists of an extracellular domain 
that recognizes and binds to specific ligands, a hydrophobic trans-membrane 
domain, involved in interactions between receptors within the cell membrane, 
and an intracellular domain that serves as the site of protein kinase activity. 
The ligands of the erbB receptors belong to the EGF-family of growth factors: 
They are characterized by the presence of an EGF-like domain, composed of 
three disulfide-bonded intra-molecular groups conferring binding specificity, 
and additional structural motifs such as immunoglobulin-like domains, 
heparin-binding sites and glycosylation sites. These growth factors have 
different affinity for the members of erbB family: EGF, transforming growth 
factor α (TGF-α) and amphiregulin (AR) specifically bind to the EGFR. Ligand 
binding induces a conformational change of the receptor ectodomain that 
allows for homo- or hetero-dimerization between EGFR and other members of 
the erbB-family and autophosphorylation of several tyrosine residues within 
the COOH-terminal tail of the receptor (Burgess et al. 2003; Hubbard 2005; 
Bianco et al. 2007; Garofalo and Rosa 2008). 
The autophosphorylated receptor initiates the recruitment to the plasma 
membrane and the activation through phosphorylation of other cytoplasmic 
substrates, which, in turn, mediate the activation of different signal 
transduction pathways depending upon type of ligand, levels of receptor 
expression and partner of EGFR dimerization. The most studied downstream 
pathways include the phosphatidylinositol-3 kinase (PI3K)/ Akt (protein kinase 
B, PKB), the Ras/extracellular signal regulated kinase (ERK) and the 
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phospholipase Cγ (PLCγ)/protein kinase C (PKC) signaling cascades. In the 
PI3K/Akt pathway, the EGFR c-terminal intracellular domain provides a 
docking site for the p85 subunit of PI3K either directly or indirectly. Upon 
activation, PI3K generates phosphatidyl-inositol-3,4,5-tris-phosphate (PIP3) 
which recruits and activates the serine-threonine kinase Akt/PKB. Phosphatase 
and tensin homolog protein (PTEN) is a lipid phosphatase that reduces Akt 
phosphorylation/activation dephosphorylating the D3 position of membrane 
PIP3. Thus, increased PI3K or reduced PTEN activity result in enhanced Akt 
function and have been reported in various human tumors. Akt controls some 
key cellular processes through phosphorylation of several downstream targets, 
such as apoptotic proteins, transcription factors, and protein kinases (Cantley 
and Neel 1999; Song et al. 2005; Bianco et al. 2007; Garofalo and Rosa 2008). 
In the Ras/ERK signaling cascade, the adaptor protein growth factor receptor 
bound protein 2 (Grb2), pre-associated with the guanine nucleotide exchange 
son of sevenless (Sos), binds to the activated EGFR, either directly or 
indirectly. Translocation of the Grb2/Sos complex to the plasma membrane 
facilitates the activation of membrane-associated small G protein Ras by Sos. 
Activated Ras induces the activation of the Raf kinase that phosphorylates and 
activates the mitogen-activated protein kinases (MAPKs). The MAPK 
superfamily of serine/threonine kinase proteins includes the ERKs, the c-Jun 
terminal kinases (JNKs) and the p38-MAPKs (Marais and Marshall 1996; 
Johnson et al. 2005; Bianco et al. 2007; Garofalo and Rosa 2008). The 
PLCγ/PKC pathway is activated through the interaction of EGFR and 
phospholipase Cγ (PLCγ), that induces hydrolysis of phosphatidylinositol 4,5-
diphosphate (PIP2) to give inositol 1,3,5-triphosphate, an important mediator 
for intracellular calcium release, and 1,2-diacylglycerol, cofactor in protein 
kinase C (PKC) activation. PKC can activate both MAPK and JNK, which in 
turn can translocate into the nucleus and phosphorylate transcription factors 
leading to inhibition of apoptosis and stimulation of cell 
proliferation  (Patterson et al. 2005; Bianco et al. 2007; Garofalo and Rosa 
2008).  
Aberrant activity of EGFR signaling pathways is associated with cancer 
development and growth and is initiated by several events, such as altered 
ligands production, receptor mutations, deletions or persistent activation. High 
levels of EGFR expression are a common feature of the malignant phenotype 
in many solid human tumors, and correlate with advanced tumor stage, poor 
prognosis, increased risk of metastasis, resistance to chemotherapy or hormone 
therapy (Baselga and Arteaga 2005; Mendelsohn and Baselga 2006; Ciardiello 
and Tortora 2008). High expression of EGFR ligands in conjunction with 
increased expression of EGFR may facilitate the development of an autocrine 
or paracrine growth pathway, contributing to carcinogenesis (Salomon et al. 
1995). EGFR overexpression may result from a variety of mechanisms, 
including increased gene transcription and gene amplification. EGFR gene 
amplification is a frequent feature of many human cancers, often accompanied 
by other structural rearrangements that cause in-frame deletions in the extra-
 7
cellular domain of the receptor. The most frequent deleted form of the human 
EGFR is the type-III variant (EGFRvIII), characterized by a deletion in the 
extra-cellular domain that leads to constitutive activation of its TK domain: 
This EGFR genetic alteration frequently occurs in some cancers, like malignant 
glioblastoma, breast, lung and ovarian carcinomas (Moscatello et al. 1995, 
Kuan et al. 2001). Besides perturbations in EGFR expression, mutations and 
ligands production, downstream intracellular signaling pathways under the 
control of the receptor are frequently altered in tumor cells, ensuring sustained 
survival, metastatic spread and resistance to either conventional or targeted 
therapies. Mutations of Ras, PI3K, PTEN or other downstream signaling 
transducers are often present in human cancers  (Shayesteh et al. 1999; Bianco 
et al. 2003; She et al. 2003; Friday et al. 2005, Bianco et al. 2006). 
The role of EGFR-related signal transduction pathways in cancer 
progression led pharmaceutical companies to devote efforts to the development 
of EGFR inhibitors, producing remarkable results in several human 
malignancies such as colorectal carcinoma (CRC), non-small cells lung cancer 
(NSCLC) and head and neck squamous cell carcinoma (HNSC). The most 
promising and well studied EGFR inhibitors are monoclonal antibodies 
(MAbs) that bind the extra-cellular domain of the receptor and compete with 
endogenous ligands, and small-molecule tyrosine kinase inhibitors (TKIs) that 
bind the intracellular portion of the receptor, generally by competing with ATP 
and inhibiting receptor autophosphorylation. They share the same target but 
display different mechanisms of action and different specificity for the EGFR: 
In fact, MAbs are exclusively specific, while TKIs are relatively specific for 
EGFR. Moreover, MAbs are able to induce EGFR internalization, down-
regulation, degradation and activation of host immune response via antibody-
dependent cell-mediated cytotoxicity (ADCC). These features may contribute 
to the observed differences in efficacy and toxicity profiles (Hynes and Lane 
2005, Imai and Takaoka 2006)). Two anti-EGFR monoclonal antibodies 
(cetuximab and panitumumab) and two small-molecule, reversible EGFR TKIs 
(gefitinib and erlotinib) have been approved in several countries for the 
treatment of various human cancer types, but more than 10 EGFR-targeting 
agents are actually in advanced clinical development (Baselga and Arteaga 
2005; Mendelsohn and Baselga 2006; Ciardiello and Tortora 2008). 
Cetuximab (IMC-225, Erbitux) is a chimeric human:murine 
immunoglobulin G1 (IgG1) MAb that binds to EGFR with higher affinity 
compared to TGF-α or EGF and is able to promote EGFR internalization and 
degradation, such inhibiting EGFR-dependent downstream signaling pathways. 
Cetuximab has a strong antitumor activity based on direct inhibition of tumor 
cell growth, induction of cell cycle perturbations with G0/G1 arrest, induction 
of apoptotic cell death, inhibition of angiogenesis, reduction of invasion 
capabilities and enhancement of radio- and chemo-sensitivity (Peng et al. 1996; 
Perrotte et al. 1999; Ciardiello et al. 1999). Moreover, the therapeutic efficacy 
of cetuximab is supported by ADCC and complement activation  (Kimura et al. 
2007). Cetuximab is the first MAb approved for clinical use in combination 
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with either chemotherapy or radiotherapy. It has been approved by several 
regulatory agencies worldwide, including the Food and Drug Administration 
(FDA) and the European Medicines Evaluation Agency (EMEA), for the 
treatment of advanced colorectal cancer refractory to irinotecan-based 
chemotherapy, alone or in combination with irinotecan in the USA or only in 
combination with irinotecan in the European Union (Galizia et al. 2007). It has 
been also approved by the FDA in February 2006 for use in combination with 
radiotherapy to treat patients with locally advanced, unresectable squamous 
cell carcinoma of the head and neck or as monotherapy for chemorefractory 
metastatic disease (Ciardiello and Tortora 2008). 
Panitumumab (ABX-EGF, Vectibix) is a fully human, high-affinity 
anti-EGFR MAb, whose antitumor activity is based on blocking ligand-binding 
and inducing EGFR internalization but not its degradation, suggesting that the 
receptor can still be recycled to the cell surface (Yang et al. 2001). It has been 
approved by several regulatory agencies worldwide, including the FDA, as 
monotherapy for third-line treatment of colorectal cancer that is refractory to 
fluoropyrimidines, oxaliplatin, or irinotecan. In December 2007, panitumumab 
has been approved by the EMEA for use in patients with colorectal cancer who 
carry a normal, wild type K-Ras gene. 
Gefitinib (ZD1839, Iressa) is a small quinazoline derivative, reversible 
inhibitor of EGFR tyrosine kinase activity. The antitumor effect is based on its 
capability to bind strongly to EGFR without inducing EGFR internalization or 
degradation and without reducing EGFR protein levels  (Baselga and Averbuch 
2000; Sirotnak et al. 2000; Ciardiello et al. 2001). After an accelerated 
approval process, gefitinib has been approved by the FDA in May 2004 for use 
as third-line treatment of NSCLC refractory to platinum-based and docetaxel-
based chemotherapy regimens, but it has been withheld from the USA market 
since June 2005. Due to the lack of a survival benefit in the ISEL (Iressa 
Survival Evaluation in Lung Cancer) study (Thatcher et al. 2005), the FDA 
restricted the use of gefitinib to patients participating in a clinical trial or 
continuing to benefit from treatment already initiated. Gefitinib has never been 
approved in the European Union, but is currently on the market in Japan, 
Korea, China and several other Asian countries. It is currently an 
investigational drug in the USA and in the European Union. However, an 
analysis of tumor samples from NSCLC patients who had a response to 
gefitinib revealed a correlation between the presence of somatic mutations in 
the EGFR TK domain and response to gefitinib. The most frequent activating 
mutations identified were in-frame deletions of amino acids 746-750 in exon 
19, amino acid substitution leucine to arginine at codon 858 (L858R) and 
leucine to glutamate at codon 861 (L861Q) in exon 21, and substitution of 
glycine to cysteine at codon 719 (G719C) in exon 19  (Lynch et al. 2004). 
First-line therapy with gefitinib administered in a genotype-directed fashion to 
chemotherapy-naive patients with advanced NSCLC harboring EGFR 
mutations resulted in very favorable clinical outcomes with good 
tolerance  (Sequist et al. 2008). 
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Erlotinib (OSI-774, Tarceva) is a small quinazoline derivative, 
reversible TKI, able to inhibit EGFR autophosphorylation. It has been 
approved by several regulatory agencies worldwide, including the FDA and the 
EMEA, as monotherapy for the treatment of locally advanced or metastatic 
NSCLC refractory to platinum-based chemotherapy  (Gridelli et al. 2007). 
Recently, erlotinib has been approved for use in combination with gemcitabine 
as first-line treatment for advanced pancreatic cancer  (Heeger 2008). 
 
 
1.2 Tumor angiogenesis as a therapeutic target. 
 
The role of the EGFR autocrine pathway in human cancers is also 
related to the regulation of tumor angiogenesis, a process that plays a key role 
in survival of cancer cells, local tumor growth and development of distant 
metastasis. In fact, the formation of new blood vessels is essential for providing 
an adequate oxygen and nutrient supply to the growing tumor mass and for 
initiating metastatic spread. The EGFR partly controls the production of 
several proangiogenic growth factors, including vascular endothelial growth 
factor (VEGF), basic fibroblast growth factor (bFGF) and metalloproteases 
(MMPs) (Goldman et al. 1993; Gille et al. 1997; Ciardiello et al. 2006). 
Besides the indirect effect of EGFR signaling on angiogenesis, several 
preclinical studies have provided evidence for direct proangiogenic effects of 
EGFR pathway. We, and others, demonstrated that stimulation of human 
endothelial cells with EGF or TGF-α induces tube formation and treatment 
with gefitinib inhibits endothelial cells proliferation, migration and tube 
formation (Hirata et al. 2002, Bianco et al. 2008). Recently, it has been 
demonstrated that phosphorylated EGFR expressed on tumor-associated 
endothelial cells is a primary target for therapy with EGFR TKIs (Kuwai et al. 
2008). Therefore, the antitumor effect of EGFR inhibitors is partially mediated 
by inhibition of tumor angiogenesis and the combination of anti-EGFR drugs 
with antiangiogenic drugs produces a synergistic effect in inhibition of VEGF 
expression and microvessels formation in human cancers (Perrotte et al. 1999; 
Bruns et al. 2000; Ciardiello et al. 2000; Ciardiello et al. 2001; Ellis 2004; 
Morelli et al. 2006). Moreover, VEGF overexpression is a major escape 
pathway used by human cancers to acquire resistance to EGFR antagonists 
(Ciardiello et al. 2004; Bianco et al. 2005; Ciardiello et al. 2006).  
VEGF is a major mediator of tumor angiogenesis in human cancers. Its 
enhanced expression is involved in the “angiogenic switch” and associated with 
increased neovascularization within the tumor, and it is triggered through 
different mechanisms, most notably hypoxia (Fontanini et al. 1997; Ferrara and 
Kerbel 2005; Folkman 2007; Melillo 2007). In mammals, the VEGF family 
consists of five members: VEGF-A (usually defined as VEGF), VEGF-B, 
VEGF-C, VEGF-D, and placental growth factor (PlGF). VEGF binds to three 
distinct VEGF receptors (VEGFRs), tyrosine kinase receptors with an 
extracellular ligand-binding domain, a trans-membrane domain, a tyrosine 
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kinase domain, and a downstream carboxy-terminal region: VEGFR-1 (Flt-1), 
VEGFR-2 (KDR, or the murine homolog Flk-1) and VEGFR-3 (Flt-4). These 
receptors are expressed on endothelial cells and regulate cell permeability, 
proliferation and differentiation, as well as on hematopoietic stem cells, 
osteoblasts and monocytes. VEGFR-2, whose expression appears mostly 
restricted to vascular endothelial cells, is the major positive signal transducer 
for both physiological and pathological angiogenesis. Ligand binding induces 
receptor dimerization and auto-phosphorylation, activating transduction 
pathways such as the Ras/MAPK and the PLCγ/PKC signaling cascades 
(Waltenberger et al. 1994; Ferrara et al. 2003; Ferrara and Kerbel 2005; 
Kowanetz and Ferrara 2006). VEGFR-1 has an higher affinity for VEGF-A, 
but its specific ligands are VEGF-B and PlGF. However, its tyrosine kinase 
activity is relatively weak, therefore it doesn’t stimulate significantly the 
proliferation of endothelial cells. Moreover, an alternative spliced, soluble form 
of VEGFR-1 is an inhibitor of VEGF activity (Ferrara et al. 2003; Ferrara and 
Kerbel 2005; Kowanetz and Ferrara 2006). Based on these evidences, it was 
initially proposed that VEGFR-1 might not be primarily a receptor transmitting 
a mitogenic signal, but rather a “decoy” receptor, able to negatively regulate 
the activity of VEGF on vascular endothelium, by preventing the binding of 
VEGF to VEGFR-2 (Park et al. 1994). Further studies demonstrated a 
synergism between VEGF and PlGF in vivo, especially under pathological 
conditions: In fact, VEGFR-1 may contribute to angiogenesis in ischemic or 
malignant diseases. This receptor is expressed on both vascular endothelial and 
macrophage-like cells and may promote inflammation, tumor growth and 
metastasis (Hiratsuka et al. 2001). The downstream signaling of VEGFR-1 is 
not fully understood mainly due to the mild biological activity of this receptor 
in culture: PI3K is one of the candidates responsible for activation and 
signaling in certain conditions (Ferrara and Kerbel 2005; Kowanetz and Ferrara 
2006; Shibuya 2006). VEGFR-3, whose ligands are VEGF-C and -D, regulates 
lymphangiogenesis and its expression in the adult seems to be largely restricted 
to lymphatic endothelial cells (Ferrara et al. 2003; Kowanetz and Ferrara 
2006).  
It has been recently demonstrated that VEGFRs are also expressed in 
some cancer cells including breast, prostate, ovarian, melanoma, NSCLC, 
pancreatic and colon cancers (Liu et al. 1995; Strizzi et al. 2001; Hasan and 
Jayson 2001; Fan et al. 2005; Sini et al. 2008). Although the precise role of 
VEGFRs in human malignancy is not completely understood, it is possible that 
the concomitant secretion of proangiogenic growth factors and the expression 
of VEGFRs support certain biological functions in cancer cells through the 
activation of autocrine loops in some human model cancers: In melanoma (Liu 
et al. 1995; Byzova et al. 2000), mesothelioma (Strizzi et al. 2001) and human 
leukemic cells (Masood et al. 2001; Dias et al. 2002), exogenous VEGF 
stimulates cancer cell proliferation and migration by activating VEGFR-2. 
Moreover, inhibition of VEGFR-1 in primary tumors prevents endothelial cell 
migration by interfering with the chemotactic response and by diminishing 
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vascular investment with perivascular cells (Lyden et al. 2001). VEGFR-1-
dependent induction of matrix MMP-9 expression in premetastatic lung 
endothelial cells and macrophages has been reported to promote lung 
metastasis (Hiratsuka et al. 2002). A recent study has shown that VEGFR-1-
positive hematopoietic bone marrow progenitors form cellular clusters at 
tumor-specific premetastatic sites before the arrival of tumor cells and dictate 
organ-specific tumor spread (Kaplan et al. 2005). Moreover, it has been shown 
that VEGFR-1 activates ERK1/2, stress-activated protein kinase/c-Jun NH2-
terminal kinase (SAPK/JNK) (Fan et al. 2005) and Src family kinases (Lesslie 
et al. 2006) to mediate growth and migration of human colorectal carcinoma 
cells. A recent study has shown that activation of VEGFR-1 in breast cancer 
cells supports their growth and survival (Wu et al. 2006).  
Since 1971, when Folkman proposed the antiangiogenesis as a novel 
anticancer strategy (Folkman 1971), several pharmacologic approaches to 
inhibit the VEGF axis have been described, and several pre-clinical and clinical 
studies demonstrated that combining anti-VEGF treatments with chemotherapy 
or radiotherapy results in greater antitumor effect than either treatment alone. 
The first antiangiogenic agent approved by the FDA is bevacizumab (Avastin), 
a humanized variant of an anti-VEGF neutralizing monoclonal antibody: In 
2004, bevacizumab was approved for the treatment of previously untreated 
metastatic colorectal cancer in combination with 5-fluorouracil-based 
chemotherapy regimens (Ferrara et al. 2004; Hurwitz et al. 2004). It has been 
also approved in combination with paclitaxel-carboplatin based regimens for 
the treatment of patients with unresectable, locally advanced, recurrent, or 
metastatic non-squamous NSCLC (Sandler et al. 2006). On February 22, 2008, 
the FDA granted accelerated approval for bevacizumab to be used in 
combination with paclitaxel for the treatment of patients who have not received 
chemotherapy for metastatic erbB2-negative breast cancer (Miller et al. 2007) 
and, more recently, for the treatment of advanced renal cell cancer in 
combination with IFN. Currently, other anti-VEGF agents are at various stages 
of clinical development (Ferrara et al. 2003; Kowanetz and Ferrara 2006). 
These include VEGF Trap, a soluble receptor targeting VEGF, VEGF-B, and 
PlGF, an antisense oligonucleotide, VEGF-AS, targeting VEGF, VEGF-C, and 
VEGF-D, and an antibody targeting PlGF.  
In addition to strategies aimed at blocking VEGF, a variety of small 
molecule TKIs targeting VEGF receptors signaling pathway including 
sorafenib (Bay 43-9006, Nexavar), sunitinib (SU11248, Sutent), and 
vandetanib (ZD6474, Zactima) have been developed. Sorafenib, initially 
developed as a Raf kinase inhibitor, was later demonstrated to inhibit several 
RTKs including VEGFRs and to show efficacy in renal cell cancer (Kowanetz 
and Ferrara 2006). Sunitinib inhibits VEGFRs, PDGFR, c-kit, and Flt-3 and 
has efficacy in imatinib-resistant gastrointestinal stromal tumor and renal cell 
carcinoma (Kowanetz and Ferrara 2006). Vandetanib is a quinazoline-
derivative able to bind and inhibit EGFR, VEGFR-2 and rearranged during 
transfection (RET) tyrosine kinases (Wedge et al. 2002; Carlomagno et al. 
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2002; Ciardiello et al. 2004; Herbst et al. 2007). Since RET activity is 
important in some types of thyroid cancer, early data with vandetanib in 
medullary thyroid cancer has led to orphan-drug designation by the regulatory 
authorities in the USA and European Union. This investigational agent is 
currently in Phase III development in NSCLC, with Phase II studies continuing 
to investigate efficacy in other tumor types, including SCLC and thyroid, 
breast, glioma and prostate cancers. By simultaneously targeting the VEGFR 
and EGFR signaling pathways, vandetanib may produce greater clinical 
benefits than targeting either pathway alone. In fact, EGFR inhibition has a 
direct effect on tumor proliferation and survival, whereas the inhibition of 
VEGFR signaling in tumor endothelial cells has indirect antitumor effects 
through inhibition of tumor angiogenesis. Furthermore, EGFR signaling 
controls both directly (Hirata et al. 2002, Bianco et al. 2008; Kuwai et al. 2008) 
and indirectly (Goldman et al. 1993; Gille et al. 1997; Ciardiello et al. 2006) 
tumor angiogenesis, and VEGFRs expression on cancer cells may sustain 
autocrine loops in some human model cancers (Liu et al. 1995; Byzova et al. 
2000; Strizzi et al. 2001; Dias et al. 2002; Fan et al. 2005; Lesslie et al. 2006; 
Wu et al. 2006). Preclinical and early clinical studies suggest that dual 
blockade of these pathways may have greater activity than blockade of either 
pathway alone (Morelli et al. 2006; Hanrahan et al. 2007; Tortora et al. 2008). 
 
 
1.3 Mechanisms of resistance to EGFR-targeted therapies. 
 
Although the approval for cancer therapy or the advanced clinical 
development of several EGFR blocking agents, demonstrating their efficacy in 
some human metastatic diseases, a relevant issue in cancer patients is the 
development of primary and secondary resistance to the anti-EGFR drugs. 
Primary or constitutive resistance refers to patients who either do not achieve 
stable disease or who progress within 6 month after an initial clinical response, 
whereas secondary or acquired resistance typically occurs after prolonged 
treatment (Morgillo et al. 2007). However, despite the differentiation between 
these two mechanisms, it is not possible to define the molecular basis of each 
type of resistance. Resistance to targeted agents may occur by mechanisms 
similar to cytotoxic agent resistance, such as inactivating metabolism, poor 
absorption, reduced drug availability or defective immune system-mediated 
functions. Actually, most relevant causes of targeted drug resistance are 
specific mutations or loss of the target, activation of alternative TK receptors 
that bypass the pathway targeted by the specific agent, independent or 
constitutive activation of intracellular molecular effectors downstream to the 
target protein and activation of tumor-induced angiogenesis (Bianco et al. 
2005; Morgillo et al. 2007; Tortora et al. 2007).  
EGFR mutations were described in various human malignancies: The 
most extensively characterized is the EGFR variant III (EGFRvIII), containing 
an in-frame deletion from exons 2 through 7 in the extracellular domain that 
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prevents the mutated receptor from binding ligands and results in constitutive 
EGFR activation and resistance to the anti-EGFR drugs (Kuan et al. 2001; 
Lorimer 2002; Learn et al. 2004). Glioblastoma cell lines expressing this 
mutated variant EGFRvIII are relatively resistant to gefitinib; higher doses and 
longer exposure to this agent are necessary to significantly decrease EGFRvIII 
phosphorylation (Kuan et al. 2001). The protective activity of EGFRvIII may 
be due to phosphorylation of Akt, which gefitinib is unable to prevent in cells 
expressing EGFRvIII (Learn et al. 2004). Conversely, for a wide majority of 
NSCLC patients with EGFR-sensitizing mutations the mechanisms of acquired 
resistance to TKIs are represented by secondary mutations in the hydrophobic 
ATP-binding pocket of the catalytic region (T790M or T766M): In fact, the 
substitution of a threonine with a bulkier amino acid, such as methionine, could 
sterically interfere with the binding of gefitinib or erlotinib (Pao et al. 2005).  
Cancer cells often simultaneously activate TK growth factor receptors 
of different families, such as insulin-like growth factor receptor-1 (IGF-1R), 
VEGFRs, and Met, the hepatocyte growth factor (HGF) receptor, leading to 
activation of redundant and often overlapping signal transduction pathways 
that impact multiple cell functions. These receptors can maintain cell survival 
by replacing EGFR function. Particularly, signaling through the IGF-1R is an 
important alternative cell survival pathway which leads to EGFR inhibitor 
resistance. For instance, glioblastoma cells with acquired resistance to the 
EGFR-TKI AG1478 display enhanced IGF-1R levels and sustained signaling 
through the PI3K/Akt pathway, and the combined targeting of IGF-1R and 
EGFR greatly enhances apoptosis and reduces the invasive potential of these 
resistant cells (Chakravarti et al. 2002). Moreover, recent studies demonstrated 
a heterodimerization of EGFR and IGF-1R as main determinant of erlotinib 
and gefitinib resistance in NSCLC cell lines (Morgillo et al. 2006; Morgillo et 
al. 2007). A role in the development of resistance to anti-EGFR drugs has been 
demonstrated also for the HGF receptor, Met: in NSCLC cell lines and 
patients, Met amplification caused gefitinib resistance by driving an erbB3-
dependent activation of PI3K pathway (Engelman et al. 2007).  
Another relevant mechanism of resistance to the anti-EGFR agents is 
the independent or constitutive activation of signaling pathways downstream to 
EGFR. Gene amplification, overexpression of downstream effectors such as 
PI3K/Akt (Shien et al. 2004; Cully et al. 2006), and/or loss or inactivating 
mutations of negative regulators such as PTEN (Bianco et al. 2003; She et al. 
2003), all lead to a persistent activation of the PI3K/Akt and Ras/MAPK 
pathways and consequent development and maintenance of an EGFR resistant 
phenotype. Particularly, a hyperactive PI3K/Akt/mTOR pathway has been 
found in tumor samples from advanced gastric cancer or colorectal cancer 
patients failing EGFR-targeted therapy. We, and others, demonstrated that 
targeting this pathway by using mTOR inhibitors such as everolimus 
(RAD001, Afinitor) and temsirolimus (CCI-779, Torisel) overcomes resistance 
to EGFR inhibitors and produces a cooperative effect with EGFR inhibitors, 
providing a valid therapeutic strategy to be tested in a clinical setting (Wang et 
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al. 2006; Bianco et al. 2008). Loss or reduction of PTEN expression occurs in 
some advanced cancers including glioblastoma, melanoma, endometrial, 
breast, ovarian, renal cell, thyroid, and a small subset of NSCLC, and is related 
to resistance to anti-EGFR drugs. The reconstitution of PTEN in PTEN-null 
cells is able to repress Akt and to inhibit tumor growth via induction of 
apoptosis or inhibition of cell proliferation (Bianco et al. 2003; She et al. 
2003). The role of Ras/MAPK signaling pathway in determining resistance to 
EGFR inhibitors is supported by the demonstration that K-Ras mutations are 
highly specific negative predictors of response to single-agent EGFR TKIs in 
advanced NSCLC and to anti-EGFR monoclonal antibodies alone or in 
combination with chemotherapy in patients with metastatic CRC (Amado et al. 
2008; Cappuzzo et al. 2008; Linardou et al. 2008). Moreover, MAPK persistent 
activation is associated with resistance to EGFR inhibitors in NSCLC and 
breast cancers (Normanno et al. 2006). Among other signaling transducers 
downstream to EGFR producing a constitutively activated pathway, high levels 
of expression of Src, a non-receptor tyrosine kinase, correlate with poor 
prognosis in solid tumors (Dehm and Bonham 2004).  
Finally, the activation of EGFR-independent, tumor-induced 
angiogenesis can be responsible for the development of resistance to anti-
EGFR therapies. We, and others, have shown that human cancer cells with 
acquired resistance to EGFR inhibitors demonstrate over-expression and 
increased secretion of VEGF (Viloria-Petit et al. 2001; Ciardiello et al. 2004). 
Human squamous cell carcinomas xenografted in SCID mice and treated 
chronically with anti-EGFR MAbs eventually develop resistance to these 
MAbs by increasing expression and secretion of VEGF (Viloria-Petit et al. 
2001). We have provided further evidence of the role played by the VEGF-
dependent pathway in the resistance to EGFR inhibitors, generating models of 
human GEO colon cancer resistant to either cetuximab or gefitinib. Analysis of 
protein expression in samples from mice xenografted with these resistant 
tumors revealed a 5-10 fold increase in the expression of cyclooxygenase-2 
(COX-2) and VEGF as compared with parental EGFR-inhibitor sensitive 
xenografts (Ciardiello et al. 2004). This notion was confirmed in colon cancer 
patients failing treatment with cetuximab, in which it has been demonstrated 
that gene expression levels of COX-2 and VEGF may be useful markers of 
clinical outcome in single-agent cetuximab treatment (Valbohmer et al. 2005).  
Primary and acquired resistance remains the most significant obstacle to 
the success of EGFR-targeted agents. Therefore, a major priority is the 
selection of patients that could benefit from an anti-EGFR therapy through the 
design of predictive tests that identify specific genetic or epigenetic alterations 
rendering tumors dependent from EGFR signaling. However, while molecular 
targeted therapy of individual tumors remains the most ambitious goal, another 
challenge is the need to identify novel, mechanism-based combinations that 
have the potential to bypass escape mechanisms and overcome resistance to 
EGFR inhibitors in relatively unselected patient populations, rendering the 
EGFR survival signaling pathway unable of recovering.  
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Combined EGFR and VEGF(Rs) targeting constitutes a good example 
of a promising combination of targeted agents that has already shown to be 
feasible in a clinical setting. In vitro and in vivo studies have demonstrated that 
simultaneous inhibition of EGFR and VEGF/VEGFRs produces antitumor 
effects in several human cancer models (Wedge et al. 2002; Jung et al., 2002; 
Morelli et al. 2006). Particularly, we have first demonstrated that an association 
of cetuximab with a human VEGF antisense 21-mer phosphorothioate 
oligonucleotide (VEGF-AS) in mice xenografted with human colon cancer 
cells results in a selective inhibition of neoangiogenesis and in a synergistic 
tumor growth inhibition (Ciardiello et al. 2000). Moreover, we have provided 
the first evidence that a single multi-targeted agent directed against EGFR-
dependent and VEGF-dependent signaling, vandetanib, could achieve the same 
results, demonstrating a strong antitumor activity also in colon cancer 
xenografts resistant to cetuximab and gefitinib (Ciardiello et al. 2004). In this 
study, we reported that chronic continuous treatment with selective anti-EGFR 
drugs of human GEO colon cancer cells propagated as s.c. xenografts in 
athymic mice results in the development of EGFR inhibitor-resistant tumors. In 
fact, although chronic administration of optimal doses of cetuximab or gefitinib 
efficiently blocked GEO tumor growth in the majority of mice, tumors slowly 
started to grow within 80-90 days, despite continuous treatment. This acquired 
resistance did not seem to be due to a loss in the expression or to a functional 
alteration of EGFR. When we established GEO tumors growing during 
treatment with cetuximab or with gefitinib as cell lines (GEO-C225-RES and 
GEO-ZD1839-RES, respectively), we found that both cells had only a modest 
reduction in the expression of cell membrane-associated EGFR compared with 
parental GEO cells. Moreover, EGFR autophosphorylation could be efficiently 
inhibited by treatment with either cetuximab or gefitinib in both EGFR 
inhibitor-resistant GEO cell lines, suggesting that a functional EGFR was 
expressed in these cells. Western blotting revealed no major change in the 
expression of the EGFR ligand TGF-α, of bcl-2, bcl-xL, p53, p27, MDM-2, 
Akt, or MAPK. However, both GEO-C225-RES and GEO-ZD1839-RES cells 
exhibited a 5-10 fold increase in the expression of COX-2 and of VEGF 
compared with GEO cells, suggesting that a contributing mechanism to GEO 
tumor growth escape from chronic EGFR inhibition could be an increased 
angiogenic potential through enhanced endothelial cell proliferation and 
permeabilization. In contrast to that reported with EGFR inhibitors, continuous 
treatment of mice bearing established GEO xenografts with vandetanib resulted 
in efficient tumor growth inhibition for the entire duration of dosing (up to 150 
days). Vandetanib activity was also determined in mice pretreated with 
gefitinib or cetuximab: After 4 weeks of treatment with EGFR inhibitors, when 
GEO tumors growth was apparent, mice were re-treated with either EGFR 
inhibitors or vandetanib. GEO tumor growth was blocked only in mice treated 
with vandetanib, whereas tumor progression was observed in mice re-treated 
with cetuximab or gefitinib. Importantly, GEO-C225-RES and GEO-ZD1839-
RES cell lines growth as xenografts in nude mice was not significantly affected 
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by treatment with either cetuximab or gefitinib but was efficiently inhibited by 
vandetanib. This activity seeemed most probably due to the inhibitory effect of  
vandetanib on VEGF signaling in endothelial cells (Ciardiello et al. 2004). 
More recently, we demonstrated that IMO, a TLR9 synthetic agonist impairing 
also EGFR signaling pathway, synergizes with bevacizumab in sensitive and 
cetuximab-resistant colon cancer xenografts (Damiano et al. 2006; Damiano et 
al. 2007). On the basis of these encouraging data several clinical studies were 
initiated. In breast cancer, a small phase II study performed in patients with 
advanced disease who were heavily pretreated with chemotherapy showed that 
the combination of bevacizumab and erlotinib is safe and has some antitumor 
activity (Dickler et al. 2004; Tortora et al. 2008). The activity and safety of the 
combination of bevacizumab and erlotinib has been also demonstrated in 
patients with platinum-refractory advanced NSCLC (Herbst et al. 2005; 
Sandler and Herbst 2006; Herbst et al. 2007). Two phase I studies in patients 
with recurrent and/or metastatic HNSCC have evaluated the safety and 
optimum dosage of bevacizumab plus erlotinib in cases heavily pretreated with 
chemotherapy and radiation therapy (Mauer et al. 2004; Vokes et al. 2006, 
Tortora et al. 2008). The Bowel Oncology with Cetuximab Antibody (BOND) 
2 study demonstrated the antitumor effect and safety of bevacizumab and 
cetuximab with or without irinotecan in patients with irinotecan-resistant CRC 
(Saltz et al. 2007; Tortora et al. 2008). The activity of vandetanib was 
demonstrated in different phase II studies in NSCLC patients. In the first study, 
vandetanib induced a significant progression-free survival prolongation when 
compared with gefinitib (Natale et al. 2006), while in the second study it was 
evaluated as second-line therapy in combination with docetaxel in patients 
previously treated with chemotherapy (Heymach et al. 2004; Heymach et al. 
2007). Therefore, although the therapeutic approach of combined 
VEGF/VEGFRs and EGFR inhibition is still investigational, the encouraging 
results from these phase I-II studies pave the way to finding the optimum 
strategy aimed at blocking EGFR and VEGF(Rs), in order to maximize 
therapeutic effects and reduce adverse effects in cancer patients. 
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2. AIM OF THE STUDY  
 
 
The purpose of this study is to examine the signaling mechanisms 
operating in human cancers with resistance to EGFR-targeted therapies and 
responsible for the lack of response to EGFR inhibitors. In fact, the constitutive 
resistance in a large number of patients and the development of acquired 
resistance in the responders represent relevant issues for the clinical utility of 
this class of targeted agents. Previous studies from my laboratory and from 
other groups demonstrated that the combined inhibition of EGFR and other 
signaling proteins could be a successful approach to efficiently inhibit 
compensatory escape pathways and overcome both intrinsic and acquired 
resistance to anti-EGFR drugs. This evidence led our group to search for 
further determinants of resistance as basis for novel therapeutic strategies.  
To this aim, we identified human cancer cell lines with different levels 
of EGFR expression and sensitivity to EGFR inhibitors. We also generated 
human cancer cell lines with acquired resistance to anti-EGFR drugs through 
continuous treatment of tumor xenografts with cetuximab or gefitinib for 14 
weeks, followed by excision of tumors and establishment of the derived cell 
lines in vitro. In fact, in a previous study we reported that chronic continuous 
treatment with selective anti-EGFR drugs of human colon cancer xenografts 
resulted in the development of EGFR inhibitor-resistant tumors, and that 
growth of the resistant tumors was efficiently inhibited by the multitargeted 
agent vandetanib. Since vandetanib is a potent inhibitor of the VEGFR-2 
tyrosine kinase, we hypothesized that this activity could be due to the 
inhibitory effect on VEGF signaling in endothelial cells (Ciardiello et al. 
2004). The EGFR inhibitor-resistant cancer cells used in our former study were 
generated by in vivo selection; however, their resistant phenotype tended to 
weaken after several in vitro passages, even in the continued presence of 
cetuximab or gefitinib. Therefore we generated new models of stable resistance 
to EGFR inhibitors through both in vivo selection and in vitro establishment of 
the derived cell lines.  
In the present study, we used the multitargeted agent vandetanib as an 
investigational tool to elucidate the molecular basis of resistance to anti-EGFR 
drugs. Therefore, we analyzed in the resistant cancer cells signal transducers 
operating under the control of EGFR-dependent and -independent pathways, 
and studied their potential involvement in EGFR-inhibition escape 
mechanisms.  
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3. MATERIALS AND METHODS  
 
 
Drugs. Vandetanib and gefitinib were kindly provided by Dr Anderson 
Ryan (AstraZeneca Pharmaceuticals Ltd, Macclesfield, UK). Cetuximab was 
supplied by ImClone Systems (New York, NY, USA). 
 
Cell lines. HUVEC (human umbilical vein endothelial cells), human 
GEO (colon carcinoma), PC3 (hormone-refractory prostate adenocarcinoma), 
MDA-MB-468 (mammary gland carcinoma) and SW480 (colon carcinoma) 
cell lines were obtained from the American Type Culture Collection 
(Manassas, VA, USA). GEO-CR (cetuximab resistant), GEO-GR (gefitinib 
resistant), and PC3-GR (gefitinib resistant) cells were established as previously 
described (Ciardiello et al. 2004). In contrast to previous EGFR-inhibitor 
resistant cancer cells (Ciardiello et al. 2004), the resulting cell lines were stably 
resistant to EGFR inhibitors retaining a resistant phenotype even after several 
in vitro passages in absence of EGFR antagonists. All cell lines were cultured 
as previously described (Ciardiello et al. 2004). 
 
Growth in soft agar. Cells (10
4 cells/well) were suspended in 0.3% 
Difco Noble agar (Difco, Detroit, MI) supplemented with complete medium, 
layered over 0.8% agar-medium base layer and treated with different 
concentrations of gefitinib, cetuximab and vandetanib. After 10–14 days, cells 
were stained with nitro blue tetrazolium (Sigma Chemical Co., Milan, Italy) 
and colonies >0.05 mm were counted (Ciardiello et al. 2001). 
 
RNA interference. Small interfering RNA (siRNA) Kits (Validated 
Stealth™ for EGFR and Select Stealth™ for VEGFR-1/Flt-1 and VEGFR-
2/KDR) were obtained from Invitrogen Life Technologies (Grand Island, NY, 
USA). A nonsense sequence was used as a negative control. For siRNA 
validation, cells were seeded into 60 mm dishes and transfected with 40 nM 
EGFR siRNA, 120 nM VEGFR-1 or VEGFR-2 siRNA, using Lipofectamine 
2000 (Invitrogen) in Opti-MEM (Invitrogen). Forty-eight hours after 
transfection Western blot analysis for EGFR, VEGFR-1 or VEGFR-2 protein 
expression was performed. The siRNA effects on cell signaling were evaluated 
through further Western blot analysis. 
For the assessment of siRNA effects on cell survival, cells were seeded 
into 24-multiwell cluster dishes and transfected with EGFR, VEGFR-1 or 
VEGFR-2 siRNA. Twenty-four hours after transfection cells treated with 
VEGFR-1 or VEGFR-2 siRNA received cetuximab 140 nM or gefitinib 5 μM 
and cell survival was determined 24 hours later. 
 
Transfection. PC3 or SW480 cells were transiently transfected with 
pcDNA3/hFlt-1 or with pcDNA3 as negative control using the specific Cell 
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Line Nucleofector Kit V for PC3 or SW480 (Amaxa, Cologne, Germany). 
Briefly, 1×106 cells were transfected with 5 μg of DNA. To confirm VEGFR-1 
expression, cells were plated in 6-multiwell cluster dishes and a Western Blot 
analysis was performed forty-eight hours after transfection; for activity 
experiments 3×104 cells were plated in each well of 24-multiwell cluster 
dishes, twenty-four hours after transfection they received gefitinib 1, 2.5 or 5 
μM and cell survival was determined 48 hours later. 
 
Cell survival assay. The culture supernatant was removed and 100 μl 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma) 
stock solution (5 mg·ml-1) was added to each well together with 400 μl of 
medium. After 4 hours of incubation, isopropanol was added and the 
absorbance measured at 570 nm. Percentage cell survival was calculated by 
dividing the mean absorbance of wells containing treated cells by that of 
untreated control wells. 
 
Kinase assays. Enzyme inhibition by vandetanib was determined by 
ProQinase GmbH (Freiburg, Germany).  IC50 values were calculated from 12 
point dose-response curves (10-4 M to 3x10-9 M).  All protein kinases were 
expressed in Sf9 insect cells as human recombinant GST-fusion proteins or 
His-tagged proteins by means of the baculovirus expression system. Kinases 
were purified by affinity chromatography using either GSH-agarose (Sigma) or 
Ni-NTH-agarose (Qiagen, Milan, Italy). The purity of the protein kinases was 
examined by SDS-PAGE/silver staining and their identity was checked by 
western blot analysis with specific antibodies or by mass spectroscopy. The 
reaction cocktail was pipetted in 5 steps in the following order: 20 μl of assay 
buffer; 10 μl of substrate (in H2O); 5 μl of vandetanib in 10% DMSO; 10 μl of 
enzyme solution; 5 μl of ATP solution (in H2O). The amounts of protein kinase 
in each assay were as follows: 100 ng VEGFR-2;  40 ng EGFR; 150 ng 
VEGFR-3; 60 ng VEGFR-1; 100 ng PDGFRβ.  After an incubation at 30° C 
for 80 minutes, the reaction was stopped with 2 % (v/v) H3PO4. All assays 
were performed with a BeckmanCoulter Biomek 2000 robotic system. 
Incorporation of 33P was determined with a microplate scintillation counter 
(Microbeta, Wallac). IC50 values were calculated using Prism 4.03 for 
Windows (Graphpad, San Diego, California, USA). 
 
Immunoprecipitation and Western blot analysis. Cell protein 
extracts were prepared from tumor or endothelial cells cultured for 24 hours in 
the presence or absence of 1 µM gefitinib, 1 µM vandetanib, or 7 nM 
cetuximab (Ciardiello et al. 2001). Protein extracts were resolved by a 4–20% 
SDS-PAGE and probed with one of the following antibodies: anti-EGFR (Ab-
12, NeoMarkers, Fremont, CA); anti-phospho-(Tyr1173)-EGFR, anti-p70S6K, 
anti-phospho-p70S6K, anti-VEGFR-2/KDR (Upstate, Billerica, MA); anti-Akt, 
anti-phospho-(Ser473)-Akt (Cell Signaling, Danvers, MA); anti-ERK1-2, anti-
phospho-ERK1-2, anti-PTEN, anti-VEGF, anti-VEGFR-1/Flt-1, anti-Met, anti-
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phospho-Met (Santa Cruz Biotechnology, Santa Cruz, CA) and anti-actin 
(Sigma-Aldrich, Milan, Italy). Phosphorylated VEGFR-2 and VEGFR-1 were 
detected by immunoprecipitation of cell proteins with anti-VEGFR-2 or anti-
VEGFR-1 antibody, resolved by a 7.5% SDS-PAGE gel and probed with the 
PY20 anti-phospho-tyrosine mAb (Upstate, Billerica, MA). Immunoreactive 
proteins were visualized by enhanced chemiluminescence (Amersham 
International, London, United Kingdom). 
 
Determination of VEGF and PlGF concentrations. The 
concentrations of VEGF and PlGF in conditioned medium from tumor cell 
lines was determined by ELISA, as previously described (Errico et al. 2004). 
The absorbance was measured at 490 nm on a microplate reader (Bio-Rad, 
Hercules, CA) and VEGF and PlGF concentrations were determined by 
interpolation of the standard curve using linear regression analysis.  
 
Reverse transcription (RT)-PCR. Total RNA was isolated from cells 
using the Trizol reagent from Invitrogen Life Technologies (Grand Island, 
N.Y., USA). RT was performed using reverse transcriptase (Supertranscript 
RT, Life Technologies, Inc., Gaithersburg, MD). To evaluate VEGFR-1/Flt-1, 
VEGFR-2/KDR and VEGF gene expression, aliquots of RT-RNA were 
amplified using primers designed on the basis of the coding sequences of the 
human mRNA (Fan et al. 2005). PCR products were visualized using ethidium 
bromide on a 1.8% agarose gel. Human glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as a control.  
 
Cell adhesion assay. To investigate the basement membrane adhesion 
capabilities of the cancer cell lines, 96-microwell bacterial culture plates were 
pre-coated with 50 µl/well of serum-free medium containing 0.1%. BSA or 
different dilutions of matrigel in cell culture medium. After 1 hour, all coating 
solutions were removed and 2×104 cells/well were plated in serum-free 
medium. Following incubation for 1 hour at 37°C in 5% CO2, cells were fixed 
and stained with a formalin/ethanol/crystal-violet fixing/staining solution, 
washed extensively, air-dried, and the dye was eluted with ethanol/acetic acid 
solution. The readings were performed at 595 nm and the values were 
normalized to background adhesion (Benelli et al. 2003). 
 
Cell migration assay. Cell migration was investigated using the 
Boyden chamber chemotaxis assay (Albini and Benelli 2007). Polycarbonate 
filters (8-µm pore size, PVP-free from Costar-Nuclepore) were manually 
coated with 50 µl of a 0.1 mg/ml solution of collagen type IV and dried 
overnight at room temperature. VEGF was used as chemoattractant, while 
serum-free medium containing 0.1% BSA was used as negative control for 
unstimulated migration. Cells were harvested and placed in the upper 
compartment of the Boyden chamber. After incubation at 37°C in 5% CO2 for 
6 hours, cells remaining on the upper surface of the filter were removed, and 
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those that migrated to the lower compartment were fixed with ethanol, stained 
with toluidine blue (Sigma-Aldrich, Milan, Italy) and quantified using 
densitometry. 
 
Wound healing assay. Cancer cell line monolayers grown to 
confluence on gridded plastic dishes were wounded by scratching with a 10 µl 
pipette tip and then cultured in the absence or presence of doxorubicin (25 
ng/ml), vandetanib (2.5 μM), gefitinib (5 μM), VEGFR-1 or VEGFR-2 siRNA, 
or with a nonsense RNA sequence (all 120 nM) for 24 hours. Under these 
conditions, all drugs except doxorubicin weakly inhibited cell proliferation. 
Since doxorubicin did not interfere with cell migration, it was used as a 
negative control. The wounds were photographed (10× objective) at 0, 8, 24 or 
48 hours (Bennett et al. 2007) and healing was quantified by measuring the 
distance between the edges using Adobe Photoshop (v. 8.0.1; Adobe System 
Inc.). The results are presented as the percentage of the total distance of the 
original wound enclosed by cells. A survival assay was performed to ensure 
that effect on wound closure reflected inhibition of cell migration and not of 
cell proliferation. 
 
Statistical analysis. The Student's t-test was used to evaluate the 
statistical significance of the results. All analyses were done with the BMDP 
New System statistical package (version 1.0) for Microsoft Windows (BMDP 
Statistical Software, Los Angeles, CA) 
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4. RESULTS AND DISCUSSION  
 
  
EGFR inhibition contributes to the antiangiogenic effect of vandetanib. 
 
Combined targeting of EGFR and VEGF(Rs) signaling cascades has 
been identified as a therapeutic approach effective in inhibiting tumor growth 
and angiogenesis, and already feasible in a clinical setting. In a previous study, 
we have provided the first evidence that a single multi-targeted agent directed 
against EGFR-dependent and VEGF-dependent signaling, vandetanib, was able 
to inhibit tumor growth in mice xenografted with tumors resistant to EGFR 
inhibitors (Ciardiello et al. 2004). Since the activation of tumor-induced 
angiogenesis has been described as one of the mechanisms responsible for the 
development of resistance to anti-EGFR therapies, we first hypothesized that 
the in vivo effect of vandetanib on resistant tumors might depend on inhibition 
of tumor angiogenesis, probably due to the interference with VEGF signaling 
in endothelial cells, more than on a direct antitumor effect.  
The role of the VEGFRs in the regulation of endothelial cell 
permeability, proliferation and differentiation in both physiological and 
pathological conditions has been widely demonstrated (Ferrara et al. 2003; 
Ferrara and Kerbel 2005; Kowanetz and Ferrara 2006). Moreover, it has been 
recently reported that EGFR signaling directly controls tumor angiogenesis. In 
fact, stimulation of human endothelial cells with EGF or TGF-α induces tube 
formation and treatment with gefitinib inhibits endothelial cells proliferation, 
migration and tube formation (Hirata et al. 2002, Bianco et al. 2008). 
Phosphorylated EGFR expressed on tumor-associated endothelial cells has 
been identified as a primary target for therapy with EGFR TKIs (Kuwai et al. 
2008). By simultaneously targeting VEGFR-2 and EGFR signaling pathways, 
vandetanib may produce a greater antiangiogenic effect than targeting either 
pathway alone. Based on this evidence, we evaluated the contribution of EGFR 
signaling to vandetanib activity on human umbilical vein endothelial cells 
(HUVEC). We first compared the effects of erlotinib and vandetanib on 
endothelial cells survival. As shown in figure 1A, vandetanib is more effective 
than erlotinib in affecting HUVEC cells survival, most likely due to inhibition 
of both VEGFR-2 and EGFR tyrosine kinases. We then analyzed vandetanib 
effects on EGFR signaling in endothelial cells. We found that vandetanib is 
able to reduce the EGF-induced phosphorylation/activation of EGFR and of its 
downstream transducers Akt and MAPK (Fig.1B). Therefore, we demonstrated 
that inhibition of EGFR signaling in endothelial cells play a key role in the 
antiangiogenic effect of vandetanib. 
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Figure 1. Effects of erlotinib or vandetanib on HUVEC endothelial cells survival and 
EGFR-dependent signaling. (A) Percent of survival of HUVEC cells treated with 
erlotinib or vandetanib 0.1, 1 or 5 µM. Results for each treatment are presented 
relative to untreated control cells. *, 2-sided P<0.001 versus control. Bars, SD. (B) 
Western blot analysis of protein expression in HUVEC cells cultured in serum-free 
medium, treated with vandetanib 1 µM for 24h and stimulated with EGF for 15 
minutes before protein extraction.  
 
 
Human cancer cell lines resistant to EGFR inhibitors are sensitive to 
vandetanib. 
 
In order to investigate resistance to EGFR inhibitors, we identified 
human cancer cell lines with different levels of EGFR expression and 
sensitivity to the anti-EGFR drugs cetuximab and gefitinib. MDA-MB-468 
human breast cancer cells express high EGFR levels, yet their growth is 
relatively resistant to gefitinib (Bianco et al. 2003) and resistant to cetuximab 
at high doses (up to 140 nM) (Fig.2A-B). This constitutive resistant phenotype 
is associated with PI3K/Akt hyperactivity, in turn related to mutation of the 
PTEN gene. GEO human colorectal cancer cells express lower EGFR levels 
and are sensitive to both cetuximab and gefitinib (IC50 <3.5 nM and 0.5 µM, 
respectively). Compared with GEO cells, PC3 cells demonstrate similar EGFR 
expression levels and sensitivity to gefitinib but are resistant to cetuximab (up 
to 140nM). Despite similar sensitivity to gefitinib, GEO cells have a functional 
wild-type PTEN gene, whereas PC3 have a deleted PTEN. 
We also generated human cancer cell lines with acquired resistance to 
anti-EGFR drugs through continuous treatment of tumor xenografts with 
cetuximab or gefitinib for 14 weeks, followed by excision of tumors and 
establishment of the derived cell lines in vitro. We demonstrated that the EGFR 
inhibitor-resistant cell lines established in this study are insensitive to 
cetuximab (GEO-CR) and gefitinib (GEO-GR, PC3-GR) at doses up to 560 nM 
and 20 µM, respectively (Fig.2A-B). They exhibited a morphology, in vitro 
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growth rate, and soft agar cloning efficiency similar to that of parental cells 
(data not shown).  
To verify whether the in vivo effect of vandetanib on resistant tumors 
might depend not only on inhibition of tumor angiogenesis, but also on a direct 
antitumor effect, we tested the in vitro sensitivity of resistant cells to 
vandetanib. As shown in figure 2C, vandetanib efficiently inhibited soft agar 
growth of all cell lines (IC50 0.1-0.5 µM), irrespective of their EGFR inhibitor 
sensitivity. Therefore, vandetanib activity on resistant tumors was based not 
only on indirect antitumor effects through endothelial cells targeting, but also 
on a direct effect on cancer cells. 
  
 
 
Figure 2. Effects of cetuximab, gefitinib, or vandetanib on growth of human cancer 
cell lines. GEO, GEO-CR, GEO-GR, PC3, PC3-GR and MDA-MB-468 cells were 
grown in soft agar and treated with the indicated concentrations of cetuximab (A), 
gefitinib (B) or vandetanib (C) each day for 3 consecutive days. Colonies were 
counted after 10-14 days. Data represent the mean (±SD) of three independent 
experiments, each performed in triplicate, and are presented relative to untreated 
control cells; while the effects of vandetanib were statistically significant versus 
control in all cell lines (2-sided P<0.0001), the effects of gefitinib and cetuximab 
treatment were statistically significant versus control in sensitive cell lines (2-sided 
P<0.0001), but not in EGFR-inhibitor resistant cell lines.  
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Resistance to EGFR inhibitors correlates with activation of downstream 
signaling pathways via EGFR-independent mechanisms. 
 
Vandetanib is a potent inhibitor of VEGFR-2, EGFR and  RET tyrosine 
kinases. It’s a common opinion that the direct effect of vandetanib on tumor 
cells is due to EGFR and RET inhibition, while VEGFR-2 inhibition accounts 
for indirect antitumor effect through endothelial cells targeting. In this study, 
we demonstrated not only that vandetanib activity on endothelial cells is 
mediated by both VEGFR-2 and EGFR inhibition, but also that the in vitro 
effect of vandetanib on resistant cells is not exclusively related to EGFR 
inhibition. In fact, in our resistant cells, the EGFR inhibition was achieved also 
after treatment with the anti-EGFR drugs cetuximab and gefitinib, that are 
totally ineffective in inhibiting cell growth. Treatment of wild-type GEO and 
PC3 cells with EGFR inhibitors strongly reduced phosphorylation of EGFR, 
and consequently of the downstream effectors Akt and MAPK. Similarly, 
vandetanib inhibited EGFR phosphorylation in both cell lines and caused an 
almost complete down-regulation of pAkt and pMAPK (Fig.3). In MDA-MB-
468 cells, gefitinib decreased the levels of pEGFR and pMAPK without any 
change in Akt phosphorylation; in contrast, vandetanib inhibited 
phosphorylation of EGFR, MAPK and Akt. Cetuximab or vandetanib treatment 
of GEO-CR cells markedly inhibited EGFR phosphorylation; however, 
vandetanib, but not cetuximab, caused a complete reduction in phospho-Akt 
and a lesser reduction in phospho-MAPK. Similar results were observed in 
GEO-GR and PC3-GR cells comparing the effects of vandetanib and gefitinib 
(Fig.3). Since Akt is one of the major positive regulators of mTOR/p70S6 
kinase (p70S6K) activity, we then analyzed downstream effectors of the 
Akt/mTOR-dependent pathway. In wild-type GEO and PC3 cells, treatment 
with gefitinib, cetuximab and vandetanib reduced p70S6K phosphorylation 
(Fig.3), consistent with the parallel decrease in Akt phosphorylation. 
Conversely, in resistant cell lines a reduced p70S6K phosphorylation was 
observed only following vandetanib treatment (Fig.3). In summary, both 
vandetanib and anti-EGFR drugs inhibited EGFR and MAPK phosphorylation, 
but only vandetanib inhibited phosphorylation of Akt kinase and of its effector 
p70S6K in resistant cells. 
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Figure 3. Effects of cetuximab, gefitinib and vandetanib on EGFR-dependent 
signaling pathways in human cancer cell lines sensitive or resistant to EGFR 
inhibitors. Western blot analysis of protein expression in cell lines treated with 
cetuximab 7 nM, gefitinib 1 µM or vandetanib 1 µM for 24 hours prior protein 
extraction. 
 
To further verify that EGFR inhibition is not sufficient to inhibit growth 
of resistant cells, we also achieved EGFR gene silencing using an EGFR 
specific RNA interference which completely suppressed EGFR expression 
(Fig.4A). In PC3-GR cells, this small interfering RNA (siRNA) was unable to 
reduce phospho-Akt and phopsho-MAPK levels, similarly to that observed 
after gefitinib tretament. In MDA-MB-468 cells, the EGFR siRNA inhibited 
MAPK, but not Akt phosphorylation/activation, reproducing also in this case 
the results obtained with gefitinib (Fig.4B).  
 
Figure 4. Effects of EGFR silencing via siRNA on EGFR-dependent signaling in 
human cancer cell lines sensitive or resistant to EGFR inhibitors. Western blot 
analysis of protein expression in PC3-GR (A) and MDA-MB-468 (B) cells 24 hours 
after treatment with 1 µM gefitinib or 1 µM vandetanib, and 48 hours after 
transfection with EGFR specific siRNA or with a nonsense RNA sequence used as a 
negative control (both 40 nM).  
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We also evaluated the effects of EGFR silencing on sensitive and 
resistant cancer cells survival. Importantly, the EGFR-specific siRNA 
markedly reduced cell survival (approximately 50%) in wild-type PC3 cells, 
whereas no effect was seen in PC3-GR and MDA-MB-468 resistant cells 
(Fig.5). 
Therefore, in the present study, treatment with gefitinib and cetuximab, 
as well as EGFR silencing via siRNA, were able to induce cell growth arrest 
only if EGFR inhibition was coupled with down-regulation of pAkt. This effect 
was not detected in resistant cell lines, in which inhibition of EGFR and Akt 
phosphorylation was only observed following vandetanib administration. This 
suggests that EGFR inhibition per se is not sufficient to induce growth 
perturbations in resistant cells, and that inhibition of Akt 
phosphorylation/activation may be the most closely associated with significant 
growth inhibition.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Effects of EGFR silencing via siRNA on survival of human cancer cell lines 
sensitive or resistant to EGFR inhibitors. Percent of survival of PC3, PC3-GR and 
MDA-MB-468 cells treated with gefitinib 5 µM, cetuximab 140 nM, EGFR targeting 
siRNA or a nonsense RNA sequence (both 40 nM). Results for each treatment are 
presented relative to untreated control cells. *, 2-sided P<0.0001 versus control and 
versus negative control. Bars, SD. 
 
 
Resistance to EGFR inhibitors does not strictly depend on PTEN 
mutational status. 
 
Constitutive activation of the PI3K/Akt pathway is commonly reported 
in human cancers (Shayesteh et al. 1999; Cully et al. 2006), and appears to 
correlate with the response to EGFR inhibitors (Shien et al. 2004). It has been 
previously demonstrated that inactivating mutations or loss of PTEN could 
result in constitutive activation of oncogenic signals through Akt, and are 
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associated with resistance to EGFR TKIs (Bianco et al. 2003; She et al. 2003). 
In fact, the lack of a functional PTEN in MDA-MB-468 cells leads to increased 
PI3K/Akt activity and resistance to gefitinib (Bianco et al. 2003). Also PC3 
cancer cells lack a functional PTEN protein, having a deleted PTEN gene; 
however, whereas MDA-MB-468 cells are insensitive to both gefitinib and 
cetuximab, PC3 are gefitinib-sensitive, suggesting that the occurrence of the 
resistant phenotype can arise from signaling pathways other than those 
regulated by PTEN. No altered expression of PTEN was observed in the 
resistant cell lines established in this study: Western blot analysis of GEO-CR, 
GEO-GR and PC3-GR cells did not reveal any difference in PTEN expression 
(Fig.6).  
 
 
 
 
 
 
Figure 6. Analysis of PTEN expression in human cancer cell lines sensitive or 
resistant to EGFR inhibitors. Western blot analysis of PTEN expression in cell lines.  
 
 
Human cancer cell lines resistant to EGFR inhibitors express VEGF 
receptors. 
 
The apparent independence of Akt activity from EGFR activation and 
the pattern of resistant cancer cells sensitivity to vandetanib suggest the 
activation of other TKRs in the EGFR inhibitor-resistant cells, highlighting the 
role that alternative signaling pathways may play in resistance to EGFR 
antagonists.  
Alternative signaling pathways that circumvent the inhibition of EGFR 
are often activated in cancer cells, a key example being IGF-1R and Met 
signaling. The association between IGF-1R over-activity and acquired 
resistance to EGFR blockade has been demonstrated for glioblastoma 
multiforme, breast, prostate and lung cancer (Chakravarti et al. 2002; Morgillo 
et al. 2006; Morgillo et al. 2007). However, in our resistant cell lines no altered 
expression of IGF-1R has been detected (data not shown). Recently, Engelman 
et collaborators (Engelman et al. 2007) showed that Met amplification leads to 
gefitinib resistance in lung cancer by activating erbB3 signaling. Met 
evaluation in our models revealed different Met protein levels, higher in GEO 
cells and lower in PC3 and MDA-MB-468 cells. Nevertheless, no difference in 
Met expression or activation status was observed between resistant and 
sensitive cell lines (Fig.7).  
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Figure 7. Analysis of pMet and Met expression in human cancer cell lines sensitive or 
resistant to EGFR inhibitors. Western blot analysis of pMet and Met expression in cell 
lines. 
 
Since the in vitro effect of vandetanib on resistant cells does not depend 
only on EGFR inhibition, other vandetanib targets may be expressed by tumor 
cells, activating escape signaling pathways able to circumvent the EGFR 
inhibition. Vandetanib is able to inhibit, in addition to EGFR, the tyrosine 
kinase activity of VEGFR-2 (Wedge et al. 2002) and RET (Carlomagno et al. 
2002); we therefore investigated the expression of these receptors in our cancer 
cells. No expression of RET was observed in any cell line (data not shown). 
VEGFR-2 expression was observed with no noticeable differences between 
parental or resistant cell lines (Fig.8A).  
To examine the potential role of VEGFRs as alternative survival 
pathways in resistant cell lines, we examined the expression of VEGFR-1 in 
resistant cells and we observed that it was increased compared with parental 
cells, both at protein and mRNA levels (Fig.8B). Since VEGFR-1 expression is 
significantly increased in cancer cells with acquired resistance to EGFR 
inhibitors, this receptor may play a potentially important role in determining 
the EGFR-inhibitor resistant phenotype.  
Figure 8. Analysis of VEGFRs expression on human cancer cell lines sensitive or 
resistant to EGFR inhibitors. (A) Analysis of VEGFR-2/KDR protein and mRNA 
expression in cell lines using Western blot (upper panel) and PCR (lower panel), 
respectively. (B) Analysis of VEGFR-1/Flt-1 protein and mRNA expression in cell 
lines using Western blot (upper panel) and PCR (lower panel), respectively. HUVEC 
were used as a positive control. 
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Therefore we investigated the involvement of VEGFRs in vandetanib 
activity on resistant cells, evaluating the effect of vandetanib on VEGFR-1 and 
VEGFR-2 autophosphorylation. We observed a strong inhibition of both 
receptors in GEO-CR, GEO-GR and PC3-GR cells (Fig.9A-B).  
Figure 9. Analysis of VEGFRs activity on human cancer cell lines sensitive or 
resistant to EGFR inhibitors. (A) Inhibition of VEGFR-2/KDR autophosphorylation in 
GEO-CR, GEO-GR and PC3-GR cells treated for 24 hours with 1 µM vandetanib. (B) 
Inhibition of VEGFR-1/Flt-1 autophosphorylation in GEO-CR, GEO-GR and PC3-GR 
cells treated for 24 hours with 1 µM vandetanib.  
 
 
To confirm vandetanib capability of inhibiting also VEGFR-1, we 
performed a kinase assay with a new kit to define the IC50 values for VEGFR-
1, -2, -3, EGFR and PDGFRβ. As summarized in Table 1, vandetanib exhibited 
a much broader inhibitory activity than reported before (Wedge et al. 2002), 
since it efficiently inhibited also VEGFR-1 (IC50 150 nM). Moreover, the 
ability to inhibit EGFR resulted almost comparable to VEGFR-2 (IC50 43 nM 
versus 38 nM, respectively). Finally, to a lesser extent, vandetanib inhibited 
also VEGFR-3 (IC50 260 nM). These data are in agreement and extend the 
results formerly reported by a different group (Manley et al. 2002), enhancing 
the multitargeting profile of vandetanib and providing a clue to its inhibitory 
activity on resistant cells overexpressing VEGFR-1. 
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Interestingly, all resistant cell lines synthesized and secreted the 
VEGFR ligands VEGF and PlGF. VEGF mRNA expression was slightly 
elevated in all resistant cell derivatives as compared to parental cell lines 
(Fig.10A). ELISA assays confirmed that both factors are consistently produced 
in all cell lines, with VEGF levels considerably higher than PlGF levels, and 
that their secretion is higher in conditioned medium derived from resistant cells 
compared to parental cells (Fig.10B-C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Analysis of VEGF and PlGF production by human cancer cell lines 
sensitive or resistant to EGFR inhibitors. (A) VEGF mRNA levels measured by PCR 
analysis in cell lines. Concentrations of secreted VEGF (B) and PlGF (C) in 
conditioned medium from each cell line were determined by ELISA. HUVEC were 
used as a positive control. 
 
 
VEGFR-1 silencing partially restores sensitivity to EGFR antagonists. 
 
To further demonstrate VEGFRs involvement in the resistance to EGFR 
inhibitors, we investigated whether a reduction of VEGFR-1 or VEGFR-2 
expression in resistant cell lines could partially restore sensitivity to cetuximab 
and gefitinib. Only PC3-GR and MDA-MB-468 were used, because of the low 
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transfection efficiency of GEO cells. We verified that transfection with 
VEGFR-1 or VEGFR-2 siRNA for 48 hours partly reduced the respective 
target protein expression (Fig.11A-B). 
 
 
Figure 11. VEGFRs silencing in human cancer cell lines resistant to EGFR inhibitors. 
Western blot analysis of VEGFR-1/Flt-1 (A) or VEGFR-2/KDR (B) in PC3-GR and 
MDA-MB-468 cells transfected with 120 nM VEGFR-1- or VEGFR-2- targeting 
siRNA, respectively, or with a nonsense RNA sequence (negative control).  
 
 
Therefore, we verified the effects of VEGFR-1 silencing on signal 
transducers activation. Intriguingly, in PC3-GR cells VEGFR-1 protein 
reduction through siRNA restored the ability of gefitinib to inhibit Akt and 
MAPK phosphorylation/activation (Fig.12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Effects of VEGFRs silencing on EGFR-dependent signaling in human 
cancer cell lines resistant to EGFR inhibitors. Western blot analysis of protein 
expression in PC3-GR cells 24 hours after treatment with 1 µM vandetanib or 1 µM 
gefitinib, and 48 hours after transfection with 120 nM VEGFR-1 targeting siRNA or 
with a nonsense RNA sequence (negative control).  
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Moreover, the reduction of VEGFR-1 expression to levels similar to 
parental/sensitive cells partially recovered the antiproliferative effect of EGFR 
inhibitors in PC3-GR and MDA-MB-468 cells, as assessed with a cell survival 
assay (Fig.13A-B). The degree of re-sensitization was approximately 35% in 
both cell lines. The reduction of VEGFR-2 expression restored sensitivity to 
EGFR inhibitors to a lesser extent (about 15%) (Fig.13A-B). Therefore, 
VEGFRs, particularly VEGFR-1, appear to play a role in the resistance to 
EGFR inhibitors, which, in turn, correlates with Akt kinase activation via 
EGFR-independent mechanisms. 
 
Figure 13. Effects of VEGFRs silencing on survival of human cancer cell lines 
resistant to EGFR inhibitors. Cell survival analysis of the VEGFR-1 siRNA 
transfected PC3-GR (A) or MDA-MB-468 (B) cells in the presence or absence of 
gefitinib 5 μM or cetuximab 140 nM. Results for each treatment are presented relative 
to untreated control cells. *, 2-sided P<0.0001 versus control and versus negative 
control. Bars, SD. 
 
 
VEGFR-1 overexpression in wild-type cells reduces sensitivity to gefitinib. 
 
To confirm VEGFR-1 contribution to the development of resistance to 
EGFR inhibitors, we transfected a full length VEGFR-1 expression vector in 
gefitinib sensitive prostate PC3 cells and colon SW480 cells, another EGFR-
expressing cell line (Ciardiello et al. 2001), and investigated whether VEGFR-
1 could confer resistance to gefitinib. In spite of the suboptimal transfection 
efficiency (about 50% of cells), an increase of VEGFR-1 expression was 
observed 48 hours after transfection in both cell lines (Fig.14A-B). 
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Figure 14. VEGFR-1 overexpression in human cancer cell lines sensitive to EGFR 
inhibitors. Western blot analysis of VEGFR-1/Flt-1 in PC3 cells (A) and in SW480 
cells (B) transfected with pcDNA3/hFlt-1 or pcDNA3 as negative control. HUVEC 
were used as a positive control. 
 
 
Importanlty, VEGFR-1 overexpression was associated with about 30% 
and 25% reduction of sensitivity to gefitinib, in PC3 and in SW480 cells 
respectively, as measured by a survival assay (Fig.15A-B). Conversely to non-
transfected cells, VEGFR-1 overexpressing cells appeared totally insensitive to 
low doses of gefitinib and their survival was only slightly inhibited by high 
doses of this drug (Fig.15A-B). 
 
 
 
Figure 15. Effects of VEGFR-1 overexpression on survival of human cancer cell lines 
sensitive to EGFR inhibitors. Cell survival analysis of PC3 (A) and SW480 (B) 
transfected cells in the presence or absence of gefitinib 1, 2.5 or 5 µM. Results for 
each treatment are presented relative to untreated control cells. *, 2-sided P<0.0001 
versus control and pCDNA3 cells treated at the same dose of gefitinib. Bars, SD. 
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Human cancer cell lines with acquired resistance to EGFR inhibitors 
display altered adhesion and migration capabilities.  
 
VEGFRs expression may influence other tumor cell capabilities, such 
as migration and adhesion. Particularly, VEGFR-1 is implicated in the 
formation of pre-metastatic niches (Kaplan et al. 2005), and may be directly 
involved in migration of tumor cells, including colorectal carcinoma (Lesslie et 
al. 2006).  
Therefore, we compare parental and VEGFR-1 overexpressing resistant 
cell lines for their migration potential. We performed wound-healing assays on 
GEO, PC3 cells and their counterparts resistant to cetuximab and gefitinib, 
respectively. GEO and GEO-CR cells migrated slowly, however GEO-CR 
exhibited a greater migration capability compared to GEO cells, reaching a 
statistically significant difference at forty-eight hours from the beginning of the 
experiment (Fig.16A). Eight hours after wound creation, an up to 50% greater 
migration capability was observed in PC3-GR compared to PC3 cells 
(Fig.16B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Analysis of migration capabilities of human cancer cell lines sensitive or 
resistant to EGFR inhibitors. Wound healing assay on GEO versus GEO-CR (A) and 
PC3 versus PC3-GR (B) cells. Cell monolayers were wounded by scratching with a 10 
µl pipette tip. The results are presented as the percentage of the total distance of the 
original wound enclosed by cells and represent the mean ± SD at 8, 24 or 48 hours. *, 
2-sided P<0.001 versus the other cell line.  
 
 
To confirm these data, we performed a Boyden chamber chemotaxis 
assay on PC3 and PC3-GR cells using VEGF (10 ng/ml) as a chemoattractant. 
PC3-GR exhibited a two-fold greater migration capability than the parental cell 
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line (Fig.17A), and cell migration was not noticeably dependent on the 
presence of exogenous VEGF. An adhesion assay confirmed that the greater 
migration capability of PC3-GR cells was not due to a greater adherence to 
membrane basement components of the Boyden chambers filters (Fig.17B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Analysis of migration and adhesion capabilities of human cancer cell lines 
sensitive or resistant to EGFR inhibitors. (A) Migration at 6 hours of PC3 and PC3-
GR cells ± VEGF, assessed using Boyden chambers. *, 2-sided P<0.0001 versus the 
other cell line at 6 hours. Bars, SD. (B) Cell adhesion of PC3 and PC3-GR cells ± 
matrigel dilutions. *, 2-sided P<0.0001 versus negative control of the same cell line 
and versus the other cell line. Bars, SD. 
 
 
VEGFRs are involved in migration of human cancer cell lines sensitive 
and resistant to EGFR inhibitors. 
 
To investigate whether the migration of resistant cells could be affected 
by VEGFRs inhibition, we performed a wound healing assay on PC3 and PC3-
GR cells, in the presence of vandetanib, gefitinib or VEGFRs-specific siRNAs. 
Treatments with doxorubicin or with a nonsense RNA sequence were used as 
negative controls. Twenty-four hours after wound creation, both PC3 and PC3-
GR cells were able to migrate and close the wound to a similar extent. Neither 
doxorubicin nor gefitinib affected migration, but vandetanib markedly reduced 
wound closure efficiency in both cell lines, particularly PC3-GR cells 
(Fig.18A-B). Whereas the slight inhibition of wound closure with VEGFR-2-
targeted siRNA did not reach statistical significance, VEGFR-1-targeted 
siRNA inhibited both PC3 (about 60%, p<0.0001) and PC3-GR (about 70% 
p<0.0001) cell migration (Fig.18A-B).  
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Therefore we have demonstrated that VEGFR-1 inhibition strongly 
interferes with cell migration, particularly in the anti-EGFR drugs resistant cell 
lines. Further studies will evaluate whether the increased migration efficiency 
and the reduced adhesion to basement membranes observed in our cancer cells 
resistant to anti-EGFR drugs and overexpressing VEGFR-1 could result in a 
greater metastatic potential. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Role of EGFR and VEGFRs in migration capabilities of human cancer cell 
lines sensitive or resistant to EGFR inhibitors. Wound healing assay on PC3 (A) and 
PC3-GR (B) cells performed after 24 hours incubation with doxorubicin (dox) 25 
ng/ml, vandetanib 2.5 μM, gefitinib 5 μM, 120 nM VEGFR-1 or VEGFR-2 targeting 
siRNA. *2-sided P<0.0001 versus control, doxorubicin and negative control. Bars, 
SD. 
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5. CONCLUSIONS  
 
 
The studies described in this thesis report several findings that may 
have clinical and therapeutic implications.  
First, using a panel of tumor cells of different types and with different 
degrees of sensitivity or resistance to EGFR inhibitors, we demonstrated that 
resistant tumors share the following common features: VEGFR-1/Flt-1 
overexpression and Akt activation, increased secretion of VEGF and PlGF, and 
augmented migration capabilities. We also provided mechanistic evidence of 
the correlation between VEGFR-1 activity and anti-EGFR drugs resistance. 
These data imply that detection of VEGFR-1 on tumor cells may dictate an 
increased ability to survive and to escape the inhibition by anti-EGFR drugs 
used in clinical practice, such as cetuximab and gefitinib.  
Another finding concerns the small molecule TKI vandetanib, whose 
main mechanisms of action were reported by our laboratory in several previous 
studies. We demonstrated that vandetanib-induced inhibition of EGFR kinase 
in endothelial cells contributes to its antiangiogenic effect. We also 
demonstrated that vandetanib is able to inhibit VEGFR-1 kinase and this 
capability plays a key role in determining its activity on EGFR drugs-resistant 
tumors. On these bases we have measured and reported a new kinase inhibition 
profile for this drug. Since vandetanib is successfully under investigation in 
several clinical studies, these data may be important for its clinical 
development. 
Taken together, the results of our studies suggest that VEGFR-1 may 
play an important role in determining the development of a resistant phenotype 
toward EGFR-selective drugs, which, in turn, correlates with Akt kinase 
activation via EGFR-independent mechanisms. Therefore vandetanib, 
inhibiting not only EGFR, but also VEGFRs in tumor cells, is able to turn off 
Akt activation and to inhibit survival and growth also in resistant cells. Our 
results further validate the clinical utility of the combined inhibition of EGFR 
and VEGFRs pathways, clarifying the molecular mechanisms which contribute 
to the efficacy of this strategy in overcoming resistance to EGFR inhibitors. 
Moreover, we demonstrated the involvement of VEGFR-1 in regulating 
other important cells function, such as adhesion and migration capabilities. 
Consequently, the therapeutic use of agents able to inhibit both EGFR and 
VEGFR-1, including, as reported in this manuscript, vandetanib, may help to 
efficiently counteracts these process, potentially interfering with metastatic 
process. 
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Vascular Endothelial Growth Factor Receptor-1Contributes to
Resistance toAnti ^Epidermal Growth Factor Receptor
Drugs in Human Cancer Cells
Roberto Bianco,1Roberta Rosa,1Vincenzo Damiano,1Gennaro Daniele,1Teresa Gelardi,1Sonia Garofalo,1
ValeriaTarallo,2 Sandro De Falco,2 DavideMelisi,1Roberto Benelli,4 Adriana Albini,5
Anderson Ryan,6 Fortunato Ciardiello,3 and GiampaoloTortora1
Abstract Purpose:The resistance to selective EGFR inhibitors involves the activation of alternative signal-
ing pathways, and Akt activation and VEGF induction have been described in EGFR inhibitor ^
resistant tumors. Combined inhibition of EGFR and other signaling proteins has become a
successful therapeutic approach, stimulating the search for further determinants of resistance
as basis for novel therapeutic strategies.
Experimental Design:We established human cancer cell lines with various degrees of EGFR
expression and sensitivity to EGFR inhibitors and analyzed signal transducers under the control
of EGFR-dependent and EGFR-independent pathways.
Results:Multitargeted inhibitor vandetanib (ZD6474) inhibited the growth and the phosphor-
ylation of Akt and its effector p70S6 kinase in both wild-type and EGFR inhibitor ^ resistant
human colon, prostate, and breast cancer cells. We found that the resistant cell lines exhibit,
as common feature, VEGFR-1/Flt-1 overexpression, increased secretion of VEGF and placental
growth factor, and augmented migration capabilities and that vandetanib is able to antagonize
them. Accordingly, a new kinase assay revealed that in addition to VEGF receptor (VEGFR)-2,
RET, and EGFR, vandetanib efficiently inhibits also VEGFR-1. The contribution of VEGFR-1 to
the resistant phenotype was further supported by the demonstration that VEGFR-1 silencing
in resistant cells restored sensitivity to anti-EGFR drugs and impaired migration capabilities,
whereas exogenous VEGFR-1 overexpression in wild-type cells conferred resistance to these
agents.
Conclusions:This study shows thatVEGFR-1contributes to anti-EGFR drug resistance in differ-
ent human cancer cells. Moreover, vandetanib inhibits VEGFR-1activation, cell proliferation, and
migration, suggesting its potential utility in patients resistant to EGFR inhibitors.
Receptor tyrosine kinases (TK), such as epidermal growth
factor receptor (EGFR), play a key role in the development
and progression of human epithelial cancers (1, 2). Increased
expression of EGFR has been widely detected in human
carcinomas and is generally associated with poor prognosis as
well as resistance to chemotherapy or hormone therapy (3–5).
Therefore, inhibition of EGFR signaling has become a valuable
anticancer strategy (3–5). Among the various anti-EGFR mo-
noclonal antibodies, cetuximab (Erbitux), a chimeric human-
mouse IgG1 monoclonal antibody, has been approved for use
in patients with advanced colorectal or head and neck cancers
(3). Several compounds have also been developed that inhibit
ligand-induced activation of EGFR TK activity; these include
gefitinib (Iressa), an orally active anilinoquinazoline under
clinical investigation (3–5).
Vascular endothelial growth factor (VEGF), a potent proan-
giogenic protein (6), binds to three distinct VEGF receptors
(VEGFR): VEGFR-1 (Flt-1), VEGFR-2 (KDR or the murine
homologue Flk-1), and VEGFR-3 (Flt-4; ref. 6). These receptors
are expressed on endothelial cells and regulate cell permea-
bility, proliferation, and differentiation (6) as well as on
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hematopoietic stem cells, osteoblasts, and monocytes. Whereas
the expression of VEGFR-2 seems mostly restricted to vascular
endothelial cells, VEGFR-1 is present in both vascular endo-
thelial and macrophage-like cells and may promote inflamma-
tion, tumor growth, and metastasis (7). Moreover, it has
recently been shown that VEGFRs are also expressed in some
cancer cells (8–10). Enhanced expression of VEGF is involved
in the ‘‘angiogenic switch’’ and associated with increased
neovascularization within the tumor; it is triggered through
different mechanisms, most notably hypoxia (11–13). In
addition, activation of EGFR signaling can result in the
increased expression of VEGF in human cancer cells (14, 15),
whereas EGFR inhibition leads to decreased secretion of VEGF
and other angiogenic growth factors, including basic fibroblast
growth factor, interleukin-8, and transforming growth factor-a
(16–19). Expression of VEGFR-1 and VEGFR-2 and their
ligands may sustain an autocrine loop in some human model
cancers. In melanoma (9, 20), mesothelioma (10), and human
leukemic cells (21), exogenous VEGF stimulates cell prolifera-
tion and migration by activating VEGFR-2. Moreover, inhibi-
tion of VEGFR-1 in primary tumors prevents endothelial cell
migration by interfering with the chemotactic response and by
diminishing vascular investment with perivascular cells (22).
The development of constitutive and acquired resistance to
EGFR inhibitors is a relevant issue in cancer patients. Cancer
cells may develop resistance to EGFR inhibitors via alternative
growth signaling pathways or constitutive activation of
downstream signaling effectors (23–25). We and others have
shown that human cancer cells with acquired resistance to
EGFR inhibitors cetuximab and gefitinib show overexpression
and increased secretion of VEGF (24, 26, 27). In addition, we
have shown that simultaneous inhibition of EGFR and VEGFR-
2 causes antitumor effects in several human cancer xenograft
models (28, 29), including those with acquired resistance to
cetuximab and gefitinib (26). To this aim, we used vandetanib/
ZD6474 (Zactima), an orally available TK inhibitor active
against VEGFR-2, EGFR, and RET kinases (26, 29–31). The
EGFR inhibitor–resistant cancer cells used in our former study
were generated by in vivo selection (26); however, their resistant
phenotype tended to weaken after several in vitro passages even
in the continued presence of cetuximab or gefitinib. Therefore,
to investigate the role of certain downstream signal transducers
in the resistance to anti-EGFR drugs, in the present study, we
generated and used tumor cell lines with different levels of
EGFR expression and stable resistance to EGFR inhibitors as
well as their sensitive counterparts.
Materials andMethods
Drugs. Vandetanib and gefitinib were kindly provided by Dr.
Anderson Ryan (AstraZeneca Pharmaceuticals Ltd.). Cetuximab was
supplied by ImClone Systems.
Cell lines. Human GEO (colon carcinoma), PC3 (hormone-
refractory prostate adenocarcinoma), MDA-MB-468 (mammary gland
carcinoma), and SW480 (colon carcinoma) cell lines were obtained
from the American Type Culture Collection. GEO-GR (gefitinib
resistant), GEO-CR (cetuximab resistant), and PC3-GR (gefitinib
resistant) cells were established as previously described (26). In contrast
to previous EGFR inhibitor–resistant cancer cells (26), the resulting cell
lines that were stably resistant to EGFR inhibitors retained a resistant
phenotype even after several passages in the absence of EGFR
antagonists. All cell lines were cultured as previously described (26).
Growth in soft agar. Cells (104 per well) were suspended in 0.3%
Difco Noble agar (Difco) supplemented with complete medium,
layered over 0.8% agar medium base layer, and treated with different
concentrations of gefitinib, cetuximab, and vandetanib. After 10 to
14 d, cells were stained with nitro blue tetrazolium (Sigma Chemical
Co.) and colonies >0.05 mm were counted (19).
RNA interference. Small interfering RNA (siRNA) kits (Validated
Stealth for EGFR and Select Stealth for VEGFR-1/Flt-1 and VEGFR-2/
KDR) were obtained from Invitrogen Life Technologies, Inc. A nonsense
sequence was used as a negative control. For siRNA validation, cells
were seeded into 60-mm dishes and transfected with 40 nmol/L EGFR
siRNA and 120 nmol/L VEGFR-1 or VEGFR-2 siRNA using Lipofect-
amine 2000 (Invitrogen) in Opti-MEM (Invitrogen). Forty-eight hours
after transfection, Western blot analysis for EGFR, VEGFR-1, or VEGFR-
2 protein expression was done. The siRNA effects on cell signaling were
evaluated through further Western blot analysis.
For the assessment of siRNA effects on cell survival, cells were seeded
into 24-multiwell cluster dishes and transfected with EGFR, VEGFR-1,
or VEGFR-2 siRNA. Twenty-four hours after transfection, cells treated
with VEGFR-1 or VEGFR-2 siRNA received 140 nmol/L cetuximab or
5 Amol/L gefitinib and cell survival was determined 24 h later.
Transfection. PC3 or SW480 cells were transiently transfected with
pcDNA3/hFlt-1 or with pcDNA3 as a negative control using the specific
Cell Line Nucleofector Kit V for PC3 or SW480 (Amaxa). Briefly,
1  106 PC3 or SW480 cells were transfected with 5 Ag DNA. To
confirm VEGFR-1 expression, cells were plated in 6-multiwell cluster
dishes and a Western blot analysis was done 48 h after transfection.
For activity experiments, 3  104 cells were plated in each well of
24-multiwell cluster dishes; 24 h after transfection, they received 1, 2.5,
or 5 Amol/L of gefitinib; and cell survival was determined 48 h later.
Cell survival assay. The culture supernatant was removed and
100 AL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(Sigma Chemical) stock solution (5 mg/mL) was added to each well
together with 400 AL of medium. After 4 h of incubation, isopropanol
Translational Relevance
We report several findings that may have relevant clinical
and therapeutic implications. First, using a panel of tumor
cells of different types and with different degrees of sensi-
tivity or resistance to epidermal growth factor receptor
(EGFR) inhibitors, we show that resistant tumors share
the following common features: vascular endothelial
growth factor receptor (VEGFR)-1/Flt-1 overexpression
and Akt activation, increased secretion of VEGF and pla-
cental growth factor, and augmented migration capabili-
ties. We also provide mechanistic evidence of the
correlation betweenVEGFR-1activity and EGFR drug resis-
tance.These data imply that detectionofVEGFR-1on tumor
cells may indicate their increased ability to survive and
invade and to escape the inhibition by EGFR inhibitorsused
in clinicalpractice, suchas cetuximab andgefitinib.Another
finding concerns the small-molecule vandetanib/ZD6474,
whose mechanisms of action have been documented
by us in several previous studies. We here show that
vandetanib is able to inhibit VEGFR-1 kinase and EGFR
drug-resistant tumors. On these bases, we have remea-
sured and reported a new kinase inhibition profile for this
drug. Because vandetanib is under investigation in several
clinical studies, these data may be important for its clinical
development.
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was added and the absorbance was measured at 570 nm. Percentage cell
survival was calculated by dividing the mean absorbance of wells
containing treated cells by that of untreated control wells.
Apoptosis detection in cultured cells. The induction of apoptosis was
measured using the Cell Death Detection ELISA Plus kit (Roche
Molecular Biochemicals; ref. 32). Briefly, cells (5  104 per well) were
seeded into 6-multiwell cluster dishes and treated on days 1 to 2 with
vandetanib (0.5 Amol/L). Each treatment was done in quadruplicate.
Absorbance readings at 405 nm were normalized for cell number and
the ratio of absorbance of treated cells to untreated cells was defined as
the apoptotic index.
Kinase assays. Enzyme inhibition by vandetanib was determined by
ProQinase GmbH. IC50 values were calculated from 12-point dose-
response curves (10-4 mol/L to 3 10-9 mol/L). All protein kinases were
expressed in Sf9 insect cells as human recombinant glutathione
S-transferase fusion proteins or His-tagged proteins by means of the
baculovirus expression system. Kinases were purified by affinity
chromatography using either reduced glutathione-agarose (Sigma
Chemical) or Ni-NTA-agarose (Qiagen). The purity of the protein
kinases was examined by SDS-PAGE/silver staining and their identity
was checked by Western blot analysis with specific antibodies or by
mass spectroscopy. The reaction cocktail was pipetted in five steps in
the following order: 20 AL of assay buffer, 10 AL of substrate (in H2O),
5 AL of vandetanib in 10% DMSO, 10 AL of enzyme solution, and 5 AL
of ATP solution (in H2O). The amounts of protein kinase in each assay
were as follows: 100 ng VEGFR-2, 40 ng EGFR, 150 ng VEGFR-3, 60 ng
VEGFR-1, and 100 ng platelet-derived growth factor receptor h. After an
incubation at 30jC for 80 min, the reaction was stopped with 2% (v/v)
H3PO4. All assays were done with a Beckman Coulter Biomek 2000
robotic system. Incorporation of 33P was determined with a microplate
scintillation counter (MicroBeta, Wallac). IC50 values were calculated
using Prism 4.03 for Windows (GraphPad).
Immunoprecipitation and Western blot analysis. Cell protein extracts
were prepared from tumor cells cultured for 24 h in the presence or
absence of 1 Amol/L gefitinib, 1 Amol/L vandetanib, or 7 nmol/L
cetuximab (19). Protein extracts were resolved by a 4% to 20% SDS-
PAGE and probed with one of the following antibodies: anti-EGFR
(Ab-12, NeoMarkers); anti –phospho-(Tyr1173)-EGFR, anti-p70S6K,
anti–phospho-p70S6K, and anti-VEGFR-2/KDR (Upstate); Akt and
anti–phospho-(Ser473)-Akt (Cell Signaling); anti–extracellular signal-
regulated kinase 1/2, anti –phospho-extracellular signal-regulated
kinase 1/2, anti–phosphatase and tensin homologue (PTEN), anti-
VEGF, anti-VEGFR-1/Flt-1, anti-Met, and anti–phospho-Met (Santa
Cruz Biotechnology); and anti-actin (Sigma-Aldrich). Phosphorylated
VEGFR-2 and VEGFR-1 were detected by immunoprecipitation of cell
proteins with anti-VEGFR-2 or anti-VEGFR-1 antibody, resolved by a
7.5% SDS-PAGE gel, and probed with the PY20 anti-phosphotyrosine
monoclonal antibody (Upstate). Immunoreactive proteins were visual-
ized by enhanced chemiluminescence (Amersham International).
Determination of VEGF and placental growth factor concentra-
tions. The concentrations of VEGF and placental growth factor (PlGF)
in conditioned medium from tumor cell lines were determined by
ELISA, as previously described (33). The absorbance was measured at
490 nm on a microplate reader (Bio-Rad) and PlGF and VEGF
concentrations were determined by interpolation of the standard curve
using linear regression analysis.
Reverse transcription-PCR. Total RNA was isolated from cells using
the Trizol reagent from Invitrogen Life Technologies. Reverse transcrip-
tion was done using reverse transcriptase (Supertranscript RT, Life
Technologies). To evaluate VEGFR-1/Flt-1, VEGFR-2/KDR, and VEGF
gene expression, aliquots of reverse transcription-RNA were amplified
using primers designed based on the coding sequences of the human
mRNA (8). PCR products were visualized using ethidium bromide on a
1.8% agarose gel. Human glyceraldehyde-3-phosphate dehydrogenase
was used as a control.
Cell adhesion assay. To investigate the basement membrane
adhesion capabilities of the cancer cell lines, 96-microwell bacterial
culture plates were precoated with 50 AL/well of serum-free medium
containing 0.1% bovine serum albumin or different dilutions of
Matrigel. After 1 h, all coating solutions were removed and
2  104 cells per well were plated in serum-free medium. Following
incubation for 1 h at 37jC in 5% CO2, cells were fixed and stained with
a formalin/ethanol/crystal violet fixing/staining solution, washed
extensively, and air dried, and the dye was eluted with ethanol/acetic
acid solution. The readings were done at 595 nm and the values were
normalized to background adhesion (34).
Cell migration assay. Cell migration was investigated using the
Boyden chamber chemotaxis assay (35). Polycarbonate filters (8-Am
pore size, polyvinyl pyrrolidone–free from Costar-Nuclepore) were
manually coated with 50 AL of a 0.1 mg/mL solution of collagen type IV
and dried overnight at room temperature. VEGF was used as chemo-
attractant, whereas serum-free medium containing 0.1% bovine serum
albumin was used as a negative control for unstimulated migration.
Cells were harvested and placed in the upper compartment of the
Boyden chamber. After incubation at 37jC in 5% CO2 for 6 h, cells
remaining on the upper surface of the filter were removed, and those
that migrated to the lower compartment were fixed with ethanol,
stained with toluidine blue (Sigma-Aldrich), and quantified using
densitometry.
Wound-healing assay. Cancer cell line monolayers grown to
confluence on gridded plastic dishes were wounded by scratching
with a 10 AL pipette tip and then cultured in the presence or absence
of doxorubicin (25 ng/mL), vandetanib (2.5 Amol/L), gefitinib
(5 Amol/L), VEGFR-1 or VEGFR-2 siRNA, or with a nonsense RNA
sequence (all 120 nmol/L) for 24 h. Under these conditions, all drugs
except doxorubicin weakly inhibited cell proliferation. Because doxo-
rubicin did not interfere with cell migration, it was used as a negative
control. The wounds were photographed (10 objective) at 0, 8, or
24 h (36), and healing was quantified by measuring the distance
between the edges using Adobe Photoshop (v.8.0.1; Adobe Systems,
Inc.). The results are presented as the percentage of the total distance of
the original wound enclosed by cells. A survival assay was done to
ensure that effect on wound closure reflected inhibition of cell
migration and not of cell proliferation.
Statistical analysis. The Student’s t test was used to evaluate the
statistical significance of the results. All analyses were done with the
BMDP New System statistical package (version 1.0) for Microsoft
Windows (BMDP Statistical Software).
Results
Human cancer cell lines resistant to EGFR inhibitors are
sensitive to vandetanib. Human cancer cell lines with different
levels of EGFR expression were identified/generated to investi-
gate resistance to EGFR inhibitors. MDA-MB-468 human breast
cancer cells express high EGFR levels, yet their growth was
relatively resistant to gefitinib (37) and resistant to cetuximab
at high doses (up to 140 nmol/L; Fig. 1A). This constitutive
resistant phenotype is associated with phosphoinositide
3-kinase/Akt hyperactivity, in turn related to mutation of the
PTEN gene. GEO human colorectal cancer cells express lower
EGFR levels and were sensitive to both cetuximab and gefitinib
(IC50, <3.5 nmol/L and 0.5 Amol/L, respectively). Compared
with GEO cells, PC3 cells show similar EGFR expression levels
and sensitivity to gefitinib but are resistant to cetuximab (up to
140 nmol/L). Despite similar sensitivity to gefitinib, GEO cells
have a functional wild-type PTEN gene, whereas PC3 have a
deleted PTEN.
The EGFR inhibitor–resistant cell lines established in this
study were insensitive to cetuximab (GEO-CR) and gefitinib
(GEO-GR and PC3-GR) at doses up to 560 nmol/L and
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20 Amol/L, respectively (Fig. 1A). They had a morphology,
in vitro growth rate, and soft agar cloning efficiency similar to
that of parental cells (data not shown). We previously showed
that vandetanib inhibits the growth of EGFR inhibitor–
resistant GEO xenografts (26). In this study, vandetanib
efficiently inhibited soft agar growth of all cell lines (IC50,
0.1-0.5 Amol/L; Fig. 1A), irrespective of their EGFR inhibitor
sensitivity, and showed potent proapoptotic activity in the
resistant cancer cells even at a dose unable to induce apoptosis
in sensitive cancer cells (Fig. 1B).
Resistance to EGFR correlates with activation of downstream
signaling pathways via EGFR-independent mechanisms. The
investigation of EGFR-dependent signaling pathways revealed
interesting differences between the cell lines. Treatment of wild-
type GEO and PC3 cells with EGFR inhibitors strongly reduced
phosphorylation of EGFR and consequently of the downstream
effectors Akt and mitogen-activated protein kinase (MAPK;
Fig. 2A). Similarly, vandetanib inhibited EGFR phosphoryla-
tion in both cell lines and caused an almost complete down-
regulation of phospho-Akt and phospho-MAPK (Fig. 2A). In
Fig. 1. Effects of cetuximab, gefitinib, or
vandetanib on growth and induction of
apoptosis of human cancer cell lines.
A, effects of cetuximab, gefitinib, or
vandetanib on the soft agar growth of GEO,
GEO-CR, GEO-GR, PC3, PC3-GR, and
MDA-MB-468 cells. Cells were treated with
the indicated concentrations of drug each
day for 3 consecutive days. Colonies were
counted after10 to14 d. Points, mean of
three independent experiments, each done
in triplicate; bars, SD. Data are presented
relative to untreated control cells.Whereas
the effects of vandetanib were statistically
significant versus control in all cell lines
(two-sided P < 0.0001), the effects of
gefitinib and cetuximab treatment were
statistically significant versus control in
sensitive cell lines (two-sided P < 0.0001)
but not in EGFR inhibitor ^ resistant cell
lines. B, effect of 0.5 Amol/L vandetanib on
the induction of apoptosis. Data are
expressed as apoptotic index (absorbance
ratio at 405 nm of treated cells/untreated
cells, normalized for the same number
of cells).
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Fig. 2. Analysis of EGFR-dependent signaling pathways in human cancer cell lines sensitive or resistant to EGFR inhibitors. A,Western blot analysis of protein expression in
cell lines treated with 7 nmol/L cetuximab, 1 Amol/L gefitinib, or1 Amol/L vandetanib for 24 h before protein extraction. B,Western blot analysis of protein expression in
PC3-GR and MDA-MB-468 cells 24 h after treatment with1 Amol/L gefitinib or1 Amol/L vandetanib and 48 h after transfection with EGFR-specific siRNA or with a
nonsense RNA sequence used as a negative control (both 40 nmol/L). C, percent of survival of PC3, PC3-GR, and MDA-MB-468 cells treated with 5 Amol/L gefitinib,
140 nmol/L cetuximab, and EGFR-targeting siRNAor a nonsense RNA sequence (both 40 nmol/L). Results for each treatment are presented relative to untreated control cells.
*, two-sided P < 0.0001versus control and versus negative control. Bars, SD.
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MDA-MB-468 cells, gefitinib decreased the levels of phospho-
EGFR and phospho-MAPK without any change in Akt
phosphorylation (37, 38); in contrast, vandetanib inhibited
phosphorylation of EGFR, MAPK, and Akt (Fig. 2A). Cetuximab
or vandetanib treatment of GEO-CR cells markedly inhibited
EGFR phosphorylation; however, vandetanib, but not cetux-
imab, caused a complete reduction in phospho-Akt and a lesser
reduction in phospho-MAPK (Fig. 2A). Similar results were
observed in GEO-GR and PC3-GR cells comparing the effects of
vandetanib and gefitinib. Although the greatest difference
between gefitinib and vandetanib was seen with phospho-
Akt, these differential drug effects were also evident for
phospho-MAPK (Fig. 2A). We then analyzed downstream
effectors of the Akt/mammalian target of rapamycin–depen-
dent pathway. In wild-type GEO and PC3 cells, treatment with
gefitinib, cetuximab, and vandetanib reduced p70S6K phos-
phorylation (Fig. 2A), consistent with the parallel decrease in
Akt phosphorylation. Conversely, in resistant cell lines, a
reduced p70S6K phosphorylation was observed only following
vandetanib treatment (Fig. 2A).
In PC3-GR cells, an EGFR-specific RNA interference, which
completely suppressed EGFR expression (Fig. 2B), was unable
to reduce phospho-Akt and phospho-MAPK levels, similarly to
what we observed after gefitinib treatment. In MDA-MB-468
cells, the EGFR siRNA inhibited MAPK, but not Akt phosphor-
ylation/activation, reproducing also in this case the results
obtained with gefitinib (Fig. 2B). Moreover, the EGFR siRNA
markedly reduced cell survival (f50%) in wild-type PC3 cells,
whereas no effect was seen in PC3-GR and MDA-MB-468
cells (Fig. 2C). This suggests that EGFR inhibition per se is
not sufficient to induce growth perturbations in resistant cells
and that inhibition of Akt phosphorylation/activation seems
to be the most closely associated with significant growth
perturbation.
It has been previously shown that the lack of a functional
PTEN in MDA-MB-468 cells leads to increased phosphoinosi-
tide 3-kinase/Akt activity and resistance to gefitinib (37).
However, Western blot analysis of GEO-CR, GEO-GR, and
PC3-GR cells did not reveal any differences in PTEN expression
(Supplementary Fig. S1A).
Recently, Engelman et al. (39) showed that Met amplification
leads to gefitinib resistance in lung cancer by activating ErbB3
signaling. Met evaluation in our models revealed different Met
protein levels, higher in GEO cells and lower in PC3 and MDA-
MB-468 cells. Nevertheless, no difference in Met expression or
activation status was observed between resistant and sensitive
cell lines (Supplementary Fig. S1B).
Human cancer cell lines resistant to EGFR inhibitors express
VEGFRs. The apparent independence of Akt activity from
EGFR activation highlights the role that alternative signaling
pathways may play in resistance to EGFR antagonists.
Vandetanib is able to inhibit, in addition to EGFR, the TK
activity of VEGFR-2 (29) and RET (30); we therefore
investigated the expression of these receptors in our cancer
Fig. 3. Analysis ofVEGFR expression and activity on human cancer cell lines sensitive or resistant to EGFR inhibitors. A, analysis ofVEGFR-2/KDR protein and mRNA
expression in cell lines usingWesternblot (top) and PCR (bottom), respectively.B, analysis ofVEGFR-1/Flt-1protein andmRNA expression in cell lines usingWesternblot (top)
and PCR (bottom), respectively. C, inhibition ofVEGFR-2/KDR autophosphorylation in GEO-CR, GEO-GR, and PC3-GR cells treated for 24 h with1 Amol/L vandetanib.
D, inhibition ofVEGFR-1/Flt-1autophosphorylation in GEO-CR, GEO-GR, and PC3-GR cells treated for 24 h with1 Amol/L vandetanib. HUVEC, human umbilical vein
endothelial cells; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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cells. No expression of RET was observed in any cell line (data
not shown). VEGFR-2 expression was observed with no
noticeable differences between parental or resistant cell lines
(Fig. 3A).
To examine the potential role of VEGFRs as alternative
survival pathways in resistant cell lines, we examined the
expression of VEGFR-1 in resistant cells and observed that it
was increased compared with parental cells, both at protein and
mRNA levels (Fig. 3B). Therefore, we analyzed the effect of
vandetanib on VEGFR-1 and VEGFR-2 autophosphorylation,
observing a strong inhibition of both receptors in GEO-CR,
GEO-GR, and PC3-GR cells (Fig. 3C and D).
To confirm vandetanib capability of inhibiting also VEGFR-
1, we did a kinase assay with a new kit to define the IC50
values for VEGFR-1, VEGFR-2, VEGFR-3, EGFR, and platelet-
derived growth factor receptor h. As summarized in Table 1,
vandetanib had a much broader inhibitory activity than
reported before (29) because it efficiently inhibited also
VEGFR-1 (IC50, 150 nmol/L). Moreover, the ability to inhibit
EGFR resulted almost comparable with VEGFR-2 (IC50, 43
versus 38 nmol/L, respectively). Finally, to a lesser extent,
vandetanib inhibited also VEGFR-3 (IC50, 260 nmol/L). These
data agree and extend the results formerly reported by a
different group (40).
Interestingly, all resistant cell lines synthesized and secreted
the VEGFR ligands VEGF and PlGF. VEGF mRNA expression
was slightly elevated in all resistant cell derivatives compared
with parental cell lines (Supplementary Fig. S2A). ELISA assays
confirmed that both factors are consistently produced in all cell
lines, with VEGF levels considerably higher than PlGF levels,
and that their secretion is higher in conditioned medium
derived from resistant cells compared with parental cells
(Supplementary Fig. S2B and C).
VEGFR-1 siRNA partially restores sensitivity to EGFR antag-
onists. To further show VEGFR involvement in the resistance
to EGFR inhibitors, we investigated whether a reduction of
VEGFR-1 or VEGFR-2 expression in resistant cell lines could
partially restore sensitivity to cetuximab and gefitinib. Only
PC3-GR and MDA-MB-468 were used because of the low
transfection efficiency of GEO cells. Transfection with VEGFR-1
or VEGFR-2 siRNA for 48 h partly reduced the respective target
protein expression (Fig. 4A and B), and VEGFR-1 protein
reduction restored the ability of gefitinib to inhibit Akt and
MAPK phosphorylation/activation in PC3-GR cells (Fig. 4C).
Importantly, the reduction of VEGFR-1 expression to levels
similar to parental/sensitive cells partially recovered the
antiproliferative effect of EGFR inhibitors in PC3-GR and
MDA-MB-468 cells, as assessed with a cell survival assay
(Fig. 4D and E). The degree of resensitization was f35% in
both cell lines. The reduction of VEGFR-2 expression restored
sensitivity to EGFR inhibitors to a lesser extent (f15%; Fig. 4D
and E). Therefore, VEGFRs, particularly VEGFR-1, seem to play
a role in the resistance to EGFR inhibitors, which, in turn,
correlates with Akt kinase activation via EGFR-independent
mechanisms.
VEGFR-1 overexpression in wild-type cells reduces sensitivity to
gefitinib. To confirm VEGFR-1 contribution to the develop-
ment of resistance to EGFR inhibitors, we transfected a full-
length VEGFR-1 expression vector in gefitinib-sensitive prostate
PC3 cells and colon SW480 cells, an other EGFR-expressing cell
line (19), and investigated whether VEGFR-1 could confer
resistance to gefitinib. In spite of the suboptimal transfection
efficiency (f50% of cells), an increase of VEGFR-1 expression
was observed 48 h after transfection in both cell lines (Fig. 5A
and B), and it was associated with about 30% and 25%
reduction of sensitivity to gefitinib, in PC3 and in SW480 cells,
respectively, as measured by a survival assay (Fig. 5C and D).
Conversely to nontransfected cells, VEGFR-1–overexpressing
cells seemed totally insensitive to low doses of gefitinib and
their survival was only slightly inhibited by high doses of this
drug (Fig. 5C and D).
Human cancer cell lines with acquired resistance to
EGFR inhibitors display altered adhesion and migration capa-
bilities. VEGFR expression may influence other tumor cell
capabilities, such as migration and adhesion. To compare
parental and resistant cell lines for their migration potential, we
did a wound-healing assay on PC3 and PC3-GR cells. Eight
hours after wound creation, an up to 50% greater migration
capability was observed in PC3-GR compared with PC3 cells
(Fig. 6A). To confirm these data, we did a Boyden chamber
chemotaxis assay on PC3 and PC3-GR cells using VEGF
(10 ng/mL) as a chemoattractant. PC3-GR exhibited a 2-fold
greater migration capability than the parental cell line (Fig. 6B),
and cell migration was not noticeably dependent on the
presence of exogenous VEGF. An adhesion assay confirmed that
the greater migration capability of PC3-GR cells was not due to
a greater adherence to membrane basement components of the
Boyden chamber filters (Fig. 6C).
VEGFRs are involved in migration of human cancer cell lines
sensitive and resistant to EGFR inhibitors. To investigate
whether the migration of resistant cells could be affected by
VEGFR inhibition, we did a wound-healing assay on PC3 and
PC3-GR cells in the presence of vandetanib, gefitinib, or
VEGFR-specific siRNAs. Twenty-four hours after wound crea-
tion, both PC3 and PC3-GR cells were able to migrate and close
the wound to a similar extent. Neither doxorubicin nor
gefitinib affected migration, but vandetanib markedly reduced
wound closure efficiency in both cell lines, particularly PC3-GR
cells (Fig. 6D). Whereas the slight inhibition of wound closure
with VEGFR-2–targeted siRNA did not reach statistical signif-
icance, VEGFR-1–targeted siRNA inhibited both PC3 (f60%;
P < 0.0001) and PC3-GR (f70%; P < 0.0001) cell migration
(Fig. 6D).
Discussion
The purpose of this study was to examine the signaling
mechanisms operating in human tumor cell lines that have
acquired resistance to anti-EGFR drugs. Although these agents
Table 1. Kinase inhibition by vandetanib
Kinase IC50 (nmol/L)
VEGFR-1 150
VEGFR-2 38
VEGFR-3 260
EGFR 43
PDGFRh 5,300
Abbreviation: PDGFRh, platelet-derived growth factor receptor h.
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Fig. 4. VEGFR silencing in human cancer cell lines resistant to EGFR inhibitors.Western blot analysis ofVEGFR-1/Flt-1 (A) orVEGFR-2/KDR (B) in PC3-GR andMDA-MB-
468 cells transfected with120 nmol/LVEGFR-1^ orVEGFR-2^ targeting siRNA, respectively, or with a nonsense RNA sequence (negative control). C,Western blot analysis
of protein expression in PC3-GR cells 24 h after treatment with1 Amol/L vandetanib or1 Amol/L gefitinib and 48 h after transfection with120 nmol/LVEGFR-1^ targeting
siRNA or with a nonsense RNA sequence (negative control). D and E, cell survival analysis of theVEGFR-1siRNA-transfected cells in the presence or absence of 5 Amol/L
gefitinib or140 nmol/L cetuximab. Results for each treatment are presented relative to untreated control cells. *, two-sided P < 0.0001versus control and versus negative
control. Bars, SD.
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have a significant antiproliferative activity, the occurrence of
resistance in the clinical setting is an issue. Specific activating
mutations within the EGFR TK domain correlate with dramatic
responses to gefitinib or erlotinib observed in some subgroups
of patients. However, with the exception of a recently shown
threonine to methionine (T790M or T766M) point mutations
in exon 20 (41), the mechanisms by which some patients
become resistant to treatment are still unclear, especially for
monoclonal antibodies.
Aberrant activation of phosphoinositide 3-kinase represents
one of the most commonly reported mechanisms by which
resistance to EGFR inhibitors arises. Inactivating mutations or
loss of PTEN could result in constitutive activation of oncogenic
signals through Akt and has been associated with resistance to
EGFR TK inhibitors (37, 38). Both MDA-MB-468 and PC3
cancer cells lack functional PTEN protein; however, whereas
MDA-MB-468 cells are insensitive to both gefitinib and
cetuximab, PC3 are gefitinib sensitive, suggesting that the
occurrence of the resistant phenotype can arise from signaling
pathways other than those regulated by PTEN; no altered
expression of PTEN was observed in the resistant lines estab-
lished in this study. Constitutive activation of the phosphoi-
nositide 3-kinase/Akt pathway is commonly reported in human
cancers (42) and seems to correlate with the response to EGFR
inhibitors (43). In the present study, treatment with gefitinib
and cetuximab, as well as EGFR silencing via siRNA, was able to
induce cell growth arrest only if EGFR inhibition was coupled
with down-regulation of phospho-Akt. This effect was not
detected in resistant cell lines, in which inhibition of EGFR and
Akt phosphorylation was only observed following vandetanib
administration. Moreover, in cancer cells with elevated activa-
tion of Akt, an enhanced mammalian target of rapamycin
activity has been detected (44). Because Akt is one of the
major positive regulators of mammalian target of rapamycin/
p70S6K activity, targeting of these kinases could represent a
promising therapeutic approach. The pattern of sensitivity to
vandetanib suggests the presence of other TKs that are activated
in EGFR inhibitor–resistant cell lines, including the VEGFRs.
Alternative signaling pathways that circumvent the inhibition
of EGFR are often activated in cancer cells, a key example being
insulin-like growth factor-I receptor and Met signaling. The
association between insulin-like growth factor-I receptor
overactivity and acquired resistance to EGFR blockade has
been shown for glioblastoma multiforme and breast and pro-
state cancer (25, 45), and Met amplification seems to sustain
the resistance against small TK inhibitors in non–small cell
lung cancer cell lines and patients independently from EGFR
mutations (39). However, in our resistant cell lines, no altered
Fig. 5. VEGFR-1overexpression in human cancer cell lines sensitive to EGFR inhibitors.Western blot analysis ofVEGFR-1/Flt-1in PC3 cells (A) and in SW480 cells (B)
transfected with pcDNA3/hFlt-1or pcDNA3 as negative control. Cell survival analysis of PC3-transfected (C) and SW480-transfected (D) cells in the presence or absence
of 1, 2.5, or 5 Amol/L of gefitinib. Results for each treatment are presented relative to untreated control cells. *, two-sided P < 0.0001versus PC3 and PC3pCDNA3 treated
at the same dose of gefitinib. Bars, SD.
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expression of insulin-like growth factor-I receptor (data not
shown) and no altered expression/activation of Met were
detected using commercial antibodies. Vandetanib is also a
potent inhibitor of RET TK activity (46), but no RET expression
was detected in any of our cancer cell lines. Because all the cell
lines expressed both VEGFR-1 and VEGFR-2 and VEGFR-1 is
significantly increased in cancer cells with acquired resistance to
EGFR inhibitors, this receptor may play a potentially important
role in determining the EGFR inhibitor–resistant phenotype.
Whereas VEGFR-2 has been characterized as one of the major
mediators of angiogenesis in human malignancy, through
induction of endothelial differentiation, DNA synthesis, and
proliferation (47), VEGFR-1 seems to function as a VEGF ‘‘sink’’
during developmental vasculogenesis and may contribute to
angiogenesis in ischemic or malignant diseases (48). In
addition to their expression on endothelial cells, VEGFRs are
expressed in hematopoietic stem cells and also in a variety of
tumor types, including breast, prostate, ovarian, melanoma,
non–small cell lung, pancreatic, and colon cancers (49). More
recently, VEGFR-1 expression has been detected in different
human prostate and colorectal cancer cell lines, including GEO
cells (8). Although the precise role of VEGFRs in human
malignancy is not completely understood, it is possible that the
concomitant secretion of proangiogenic growth factors and the
expression of VEGFRs support certain biological functions in
cancer cells through the activation of autocrine loops (50). All
the cell lines used in the present study secreted both VEGF and
PlGF, the major growth factors that stimulate and activate
VEGFR-1 or VEGFR-2. To further investigate the inhibitory
effect observed with vandetanib on our resistant cell lines, we
reevaluated the kinase inhibitory profile of this agent using a
novel kinase assay. We had previously reported a strong
Fig. 6. Analysis of migration and adhesion capabilities of human cancer cell lines sensitive or resistant to EGFR inhibitors. A, wound-healing assay on PC3 and PC3-GR
cells. Cell monolayers were wounded by scratchingwith a10 AL pipette tip.The results are presented as the percentage of the total distance of the original wound enclosedby
cells. Points, mean at 8 h; bars, SD. *, two-sided P < 0.0001versus the other cell line at 8 h. B, migration at 6 h of PC3 and PC3-GR cellsFVEGF, assessed using Boyden
chambers. *, two-sidedP < 0.0001versus the other cell line at 6 h.C, cell adhesionof PC3 and PC3-GRcellsFMatrigel. *, two-sidedP < 0.0001versus negative control of the
same cell line and versus the other cell line. D, wound-healing assay in PC3 and PC3-GR cells done after 24 h of incubation with 25 ng/mL doxorubicin (Dox), 2.5 Amol/L
vandetanib, 5 Amol/L gefitinib, and120 nmol/LVEGFR-1^ orVEGFR-2^ targeting siRNA. *, two-sided P < 0.0001versus control, doxorubicin, and negative control. Bars, SD.
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inhibitory activity against VEGFR-2 and RET and, at lesser
extent, on EGFR kinases (29, 30). We have now shown that
vandetanib efficiently inhibits also VEGFR-1 and that the
inhibitory activity on EGFR is higher than formerly reported;
moreover, vandetanib at a much lesser extent inhibits also
VEGFR-3. These data agree with a previous analysis from a
different group (40), enhancing the multitargeting profile of
vandetanib and providing a clue to its inhibitory activity on
resistant cells overexpressing VEGFR-1. In the same fashion,
we have shown that siRNA silencing of VEGFRs may result in
decreased cancer cell survival. Intriguingly, inhibition of
VEGFR-1 activity correlates with a partially restored sensitivity
to anti-EGFR drugs in EGFR inhibitor–resistant cancer cells. In
fact, VEGFR-1 silencing restores gefitinib ability to inhibit both
Akt activation/phosphorylation and cell survival. By contrast,
exogenous overexpression of VEGFR-1 in two different tumor
cell lines markedly reduces the sensitivity to EGFR inhibitors.
VEGFR-1 is implicated in the formation of premetastatic
niches (51) and may be directly involved in migration of tumor
cells, including colorectal carcinoma (52). Therefore, the
increased migration efficiency and the reduced adhesion to
basement membranes observed in our cancer cells resistant to
anti-EGFR drugs and overexpressing VEGFR-1 could result in a
greater metastatic potential. In this respect, we have shown that
VEGFR-1 inhibition strongly interferes with cell migration,
particularly in the anti-EGFR drug-resistant cell lines.
Taken together, the results of our studies suggest that VEGFR-
1 may play an important role in determining the development
of a resistant phenotype toward EGFR-selective drugs, affecting
also adhesion and migration processes. Consequently, the
therapeutic use of agents able to inhibit both EGFR and VEGFR-
1, including, as reported in this article, vandetanib, may help to
efficiently inhibit Akt phosphorylation/activation, antagonizing
and overcoming EGFR inhibitor resistance, thus affecting also
the microenvironment.
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